In this chapter, the term ‘renal osteodystrophy’ will be used in a generic sense to include all the clinical syndromes of skeletal disease and altered calcium (Ca) and phosphorus (P) homeostasis resulting from chronic renal failure (CRF). The skeletal pathology can include osteitis fibrosa and other features of secondary hyperparathyroidism, osteomalacia, aplastic or adynamic bone disease, osteoporosis, osteosclerosis, and in children, retardation of growth. Emphasis will be placed on the manifestations of these syndromes that occur in patients on maintenance dialysis with a consideration of pathogenesis, prevention and management


Parathyroid Gland Uremic Patient Renal Osteodystrophy Osteitis Fibrosa Adynamic Bone Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holick MF, McNeill SC, MacLaughlin JA et al: The physiologic implications of the formation of previtamin D3 in skin. Trans Assoc Am Phys 92: 54, 1979PubMedGoogle Scholar
  2. 2.
    Gray, RW, Omdahl JL, Ghazarian JG, DeLuca HF: 25-hydroxycholecalciferol-1-hydroxylase. J Biol Chem 247: 7528, 1972PubMedGoogle Scholar
  3. 3.
    Hughes MR, Haussler MR, Wergedal J, Baylink DJ: Regulation of plasma 1 alpha,25-dihydroxyvitamin D3 by calcium and phosphate. Clin Res 23: 323A, 1975Google Scholar
  4. 4.
    Haussler MR, McCain TA: Basic and clinical concepts related to vitamin D metabolism and action. N Eng J Med 297: 974, 1041, 1977Google Scholar
  5. 5.
    Cantley LK, Russell J, Lettieri D, Sherwood LM: 1,25(OH)2 D-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 117: 2114, 1985PubMedGoogle Scholar
  6. 6.
    DeLuca HF: Vitamin D endocrinology. Ann Intern Med 85: 367, 1976PubMedGoogle Scholar
  7. 7.
    Mayer GP, Hurst JG: Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 102: 1036, 1978PubMedGoogle Scholar
  8. 8.
    Mayer GP, Habener JF, Potts JF: Parathyroid hormone secretion in vivo demonstration of a calcium-independent nonsuppressible component of secretion. J Clin Invest 57: 678, 1976PubMedGoogle Scholar
  9. 9.
    Mayer GP, Hurst JG, Barto JA, Keaton JA, Moore MP: Effect of epinephrine on parathyroid hormone secretion in calves. Endocrinology 104: 1181, 1979PubMedGoogle Scholar
  10. 10.
    Habener JF, Potts JT Jr: Relative effectiveness of magnesium hormone in vitro. Endocrinology 98: 197, 1976PubMedGoogle Scholar
  11. 11.
    Habener JF, Mayer GP, Dee PC, Potts JT Jr: Metabolism of amino-and carboxyl-sequence immunoactive parathyroid hormone in the bovine: evidence for peripheral cleavage of hormone. Metabolism 25: 385, 1976PubMedGoogle Scholar
  12. 12.
    Martin KJ, Hruska K, Freitag JJ, Klahr S, Slatapolsky E: The peripheral metabolism of parathyroid hormone. N Engl J Med 301: 1092, 1979PubMedCrossRefGoogle Scholar
  13. 13.
    Slatopolsky E, Caglar S, Pennell JP et al.: On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 50: 492, 1971PubMedGoogle Scholar
  14. 14.
    Russell J, Lettieri D, Sherwood LM: Direct regulation by calcium of cytoplasmatic messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. J Clin Invest 72: 1851, 1983PubMedGoogle Scholar
  15. 15.
    Yamamoto M, Igarashi T, Muramatsu M et al.: Hypocalcemia increases and hypercalcemia decreases the steady state level of parathyroid hormone messenger ribonucleic acid in the rat. J Clin Invest 83: 1053, 1989PubMedGoogle Scholar
  16. 16.
    Pitts TO, Piraino BH, Mitro R et al.: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876, 1988PubMedGoogle Scholar
  17. 17.
    Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162, 1991PubMedGoogle Scholar
  18. 18.
    Wilson L, Felsenfeld AJ, Drezner MK, Llach F: Altered divalent ion metabolism in early renal failure: Role of 1,25-(OH)2D. Kidney Int 27: 565, 1985PubMedGoogle Scholar
  19. 19.
    Lopez-Hilker S, Galceran T, Chan Y-L et al.: Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 78: 1097, 1986PubMedGoogle Scholar
  20. 20.
    Kaplan MA, Canterbury JM, Jaffe D: Effect of dietary phosphorus (P) in the phosphaturic and calcemic response to parathyroid hormone (PTH) in the uremic dog. Kidney Int 18: 77, 1977Google Scholar
  21. 21.
    Tennant BJ, Lowe JE, Tasker JB: Hypercalcemia and hypophosphatemia in ponies following bilateral nephrectomy. Proc Soc Exp Biol Med 167: 365, 1981PubMedGoogle Scholar
  22. 22.
    Slatopolsky E, Caglar S, Gradowska L: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using ‘proportional reduction’ of dietary phosphorus intake. Kidney Int 2: 147, 1972PubMedGoogle Scholar
  23. 23.
    Bricker NS: trade off hypothesis. N Engl J Med 286: 1093, 1972PubMedCrossRefGoogle Scholar
  24. 24.
    Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL: The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest 49: 2146, 1970PubMedGoogle Scholar
  25. 25.
    Jowsey J, Reiss E, Canterbury JM: Long term effects of high phosphate intake on parathyroid hormone levels and bone metabolism. Acta Orthop Scand 45: 801, 1974PubMedGoogle Scholar
  26. 26.
    Fournier AE, Johnson WJ, Taves DR: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors. J Clin Invest 50: 592, 1971PubMedGoogle Scholar
  27. 27.
    Fournier AE, Arnaud CD, Johnson WJ et al.: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 50: 599, 1971PubMedCrossRefGoogle Scholar
  28. 28.
    Llach F, Massry SG: On the mechanism of the prevention of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601, 1985PubMedGoogle Scholar
  29. 29.
    Maschio G et al.: Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy. Am J Clin Nutr 33: 1546, 1980PubMedGoogle Scholar
  30. 30.
    Goldman R, Bassett SH: Phosphorus excretion in renal failure. J Clin Invest 33: 1623, 1954PubMedGoogle Scholar
  31. 31.
    Slatopolsky E, Gradowska L, Kashemsant C et al.: The control of phosphate excretion in uremia. J Clin Invest 45: 672, 1966PubMedGoogle Scholar
  32. 32.
    Adler AJ, Ferran N, Berlyne GM: Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the ‘trade-off hypothesis’. Kidney Int 28: 932, 1985PubMedGoogle Scholar
  33. 33.
    Hebert LA, Lemann J, Petersen JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 45: 1886, 1966PubMedGoogle Scholar
  34. 34.
    Portale AP, Halloran BP, Murphy MM, Morris RC Jr: Oral intake of phosphorus can determine the serum concentration of 1,25 D by determining its production rate in humans. J Clin Invest 77: 7, 1986PubMedGoogle Scholar
  35. 35.
    Rodriguez M, Martin-Malo A, Martinez ME et al.: Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 40: 1055, 1991PubMedGoogle Scholar
  36. 36.
    Lucas PA, Brown RC, Woodhead JS, Coles G: 1,25 dihydroxycholecalciferol and parathyroid hormone in advanced renal failure: effect of simultaneous protein and phosphorus restriction. Clin Nephrol 25: 7, 1986PubMedGoogle Scholar
  37. 37.
    Tessitore N, Venturi A, Adami S et al.: Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Miner Electrolyte Metab 13: 38, 1987PubMedGoogle Scholar
  38. 38.
    Rodriguez M, Felsenfeld AJ, Dunlay R et al.: The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2: 1014, 1991PubMedGoogle Scholar
  39. 39.
    Yi H, Fukagawa M, Kurokawa K: Mild dietary phosphorus restriction directly prevents enhanced parathyroid hormone secretion and synthesis and proliferation of parathyroid cells in chronic renal failure in rats. J Am Soc Nephrol 3: 703, 1992Google Scholar
  40. 40.
    Evanson JM: The response to the infusion of parathyroid extract in hypocalcemic states. Clin Sci 31: 63, 1966PubMedGoogle Scholar
  41. 41.
    Massry SG, Coburn JW, Lee DBN et al.: Skeletal resistance to parathyroid hormone in renal failure: study in 105 human subjects. Ann Intern Med 78: 357, 1973PubMedGoogle Scholar
  42. 42.
    Christiansen C: Chronic renal failure and vitamin D metabolites: a status report. J Steroid Biochem 19: 517, 1983PubMedGoogle Scholar
  43. 43.
    Fraser DR, Kodicek E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228: 764, 1970PubMedGoogle Scholar
  44. 44.
    Gray R, Boyle I, DeLuca HF: Vitamin D metabolism: The role of kidney tissue. Science 172: 1232, 1971PubMedGoogle Scholar
  45. 45.
    Mawer EB, Backhouse J, Taylor CM: Failure of formation of 1,25 dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1: 626, 1973PubMedGoogle Scholar
  46. 46.
    Schaefer K et al.: Metabolism of 1,2 H3-4-C14-cholecalciferol in normal, uremic and anephric subjects. Isr J Med Sci 8: 80, 1972PubMedGoogle Scholar
  47. 47.
    Mason RS, Lissnered, Wilkinson M, Posen S: Vitamin D metabolites and their relationship to azotemic osteodys-trophy. Clin Endocrinol 13: 375, 1980Google Scholar
  48. 48.
    Brickman AS, Coburn JW, Massry SG, Norman AW: 1,25 dihydroxyvitamin D3 in normal man and patients with renal failure. Ann Intern Med 80: 161, 1974PubMedGoogle Scholar
  49. 49.
    Brickman AS, Coburn JW, Norman AW: Action of 1,25 dihydroxycholecalciferol, a potent, kidney produced metabolite of vitamin D3 in uremic man. N Engl J Med 287: 891, 1972PubMedCrossRefGoogle Scholar
  50. 50.
    Portale AP, Booth BE, Halloran BP, Morris RC Jr: Effect of dietary phosphorus on circulating concentrations of 1,25 dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 1580, 1984PubMedGoogle Scholar
  51. 51.
    Chesney RW, Hamstra AJ, Mazess RB: Circulating vitamin D metabolite concentrations in childhood renal diseases. Kidney Int 21: 65, 1982PubMedGoogle Scholar
  52. 52.
    Mora-Palma FJ, Lorenzo Sellares V, Ellis HL et al.: Osteomalacia in chronic renal failure before dialysis. Proc Eur Dial Transplant Assoc 19: 188, 1983PubMedGoogle Scholar
  53. 53.
    Cheung AK, Manolagas SC, Catherwood BC et al.: Determinants of serum 1,25 (OH)2D levels in renal disease. Kidney Int 24: 104, 1983PubMedGoogle Scholar
  54. 54.
    Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264, 1973PubMedGoogle Scholar
  55. 55.
    Chan YL, McKay C, Dye E, Slatopolsky E: The effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int 3827: 2732, 1986Google Scholar
  56. 56.
    Hsu CH, Patel S, Young EW, Simpson RU: Production and degradation of calcitriol in renal failure rats. Am J Physiol 253: F1015, 1987PubMedGoogle Scholar
  57. 57.
    Hsu CH, Patel S, Buchsbaum BL: Calcitriol metabolism in patients with chronic renal failure. Am J Kidney Dis 17: 185, 1991PubMedGoogle Scholar
  58. 58.
    Hsu CH, Patel SR, Young EW: Mechanism of decreased calcitriol degradation in renal failure. Am J Physiol 262: F192, 1992PubMedGoogle Scholar
  59. 59.
    Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol. Kidney Int 34: 368, 1988PubMedGoogle Scholar
  60. 60.
    Dusso A, Finch J, Delmez J, Rapp N et al.: Extrarrenal production of calcitriol. Kidney Int 38: S36, 1990Google Scholar
  61. 61.
    Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic ac id for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82: 4270, 1985PubMedGoogle Scholar
  62. 62.
    Silver J, Naveh-Many T, Mayer H: Regulation by vitamin D metabolites of parathyroid hormone gene in vivo by the rat. J Clin Invest 78: 1296, 1986PubMedCrossRefGoogle Scholar
  63. 63.
    Shvil Y, Naveh-Many T, Barach P, Silver J: Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1: 99, 1990PubMedGoogle Scholar
  64. 64.
    Slatopolsky E, Weerts C, Thielan J et al.: Marked suppression of secondary hyperparthyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136, 1984PubMedGoogle Scholar
  65. 65.
    Delmez JA, Tindira C, Grooms P et al.: Parathyroid hormone suppression by intravenous 1,25 Dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 83: 1349, 1989PubMedGoogle Scholar
  66. 66.
    Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis patients. Kidney Int 36: 1093, 1989PubMedGoogle Scholar
  67. 67.
    Okazaki T, Igarashi T, Kronenberg KM: 5’ Flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J Biol Chem 263: 2203, 1988PubMedGoogle Scholar
  68. 68.
    Merke J, Hugel U, Zlotkowski A et al.: Diminished parathyroid 1,25-(OH)2D3 receptors in experimental uremia. Kidney Int 32: 350, 1987PubMedGoogle Scholar
  69. 69.
    Korkor AB: Reduced binding of 3(H)l,25-dihydroxyvitamin D3 in the parathyryoid glands of patients with renal failure. N Engl J Med 316: 1573, 1987PubMedCrossRefGoogle Scholar
  70. 70.
    Malmaeus J, Grimelius L, Johansson H et al.: Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. Scand J Urol Nephrol 18: 157, 1984PubMedGoogle Scholar
  71. 71.
    St. Goar WT: Case records of the Massachusetts Genrul Hospital. N Engl J Med 268: 943, 1963CrossRefGoogle Scholar
  72. 72.
    McPhaul H, McIntosh DA, Hammond WS, Park OK: Autonomous secondary hyperparathyroidism. N Engl J Med 271: 1342, 1964PubMedCrossRefGoogle Scholar
  73. 73.
    Tanaka Y, Seo H, Tominaga Y et al.: Factors related to the recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism. Surg Today 23: 220, 1993PubMedGoogle Scholar
  74. 74.
    Fukuda N, Tanaka H, Tominaga Y et al.: Decreased 1,25-Dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436, 1993PubMedGoogle Scholar
  75. 75.
    Martin KJ, Hruska KA, Greenwalt A, Slatopolsky E: Selective uptake of intact parathyroid hormone by the liver. Differences between hepatic and renal uptake. J Clin Invest 58: 781, 1976PubMedGoogle Scholar
  76. 76.
    Catherwood BD et al.: Sites of clearance of endogenous parathyroid hormone in the vitamin D deficient dog. Endocrinology 98: 228, 1976PubMedGoogle Scholar
  77. 77.
    Hruska KA, Kopelman R, Rutherford WE: Metabolism of immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest 56: 39, 1975PubMedGoogle Scholar
  78. 78.
    Zull JE, Chuang J: Characterization of parathyroid hormone fragments produced by cathepsin D. J Biol Chem 260: 1608, 1985PubMedGoogle Scholar
  79. 79.
    Freitag JJ, Martin KJ, Hruska KA et al.: Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 298: 29, 1978PubMedCrossRefGoogle Scholar
  80. 80.
    Segre GV, Sherrard DJ, Carlton EI: Use of the PTH (IRMA) assay in patients with impaired renal function and renal osteodystrophy, San Juan Capistrano, Nichols Institute, 1990, p 1Google Scholar
  81. 81.
    Mayer GP, Hurst JG: Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 102: 1036, 1978PubMedGoogle Scholar
  82. 82.
    Voigts A, Felsenfeld AJ, Andress DL, Llach F: Parathyroid hormone and bone histology: response to hypocalcemia in osteitis fibrosa. Kidney Int 25: 445, 1984PubMedGoogle Scholar
  83. 83.
    Brown EM, Wilson RE, Eastman R: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54: 172, 1982PubMedGoogle Scholar
  84. 84.
    Malberti F, Surian M, Cosci P: Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 7: 822, 1992PubMedGoogle Scholar
  85. 85.
    Coburn JW, Hartenbower DL, Massry SG: Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int 4: 96, 1973PubMedGoogle Scholar
  86. 86.
    Sherrard DJ, Baylink DJ, Wergedal JE, Maloney NA: Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 39: 119, 1974PubMedGoogle Scholar
  87. 87.
    Eastwood JB, Harris E, Stamp TCB, De Wardener H: Vitamin D deficiency in the osteomalacia of chronic renal failure. Lancer 2: 1209, 1976Google Scholar
  88. 88.
    Offerman G, v. Herrath D, Schaefer K: Serum 25 hydroxycholecalciferol in uremia. Nephron 13: 269, 1974Google Scholar
  89. 89.
    Baylink DJ, Stauffer J, Wergedal JE, Rich C: Formation, mineralization and resorption of bone in vitamin D deficient rats. J Clin Invest 49: 112, 1970Google Scholar
  90. 90.
    Kanis JA, Cundy T, Bartlett M: Is 24,25 dihydroxychole-calciferol a calcium regulating hormone in man? Br Med 71: 1382, 1978Google Scholar
  91. 91.
    Llach F, Brickman AS, Singer FR, Coburn JW; 24,25-Dihydroxycholecalciferol, a vitamin D sterol with qualitatively unique effects in uremic man. Metab Bone Dis Rel Res 2: 11, 1979Google Scholar
  92. 92.
    Alfrey AC, Hegg A, Craswell P: Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 33: 1509. 1980PubMedGoogle Scholar
  93. 93.
    Wills MR, Savory J: Aluminum poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet 2: 29, 1983PubMedGoogle Scholar
  94. 94.
    Parkinson IS, Feest TG, Ward MK: Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet 1: 406, 1979PubMedGoogle Scholar
  95. 95.
    Siddiqui JY, Simpson W, Ellis HA, Kerr DNS: Fluoride and bone disease in patients on regular haemodialysis. Proc Eur Dial Transplant Assoc 8: 149, 1971Google Scholar
  96. 96.
    Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalopathy syndrome, possible aluminum intoxication. N Engl J Med 294: 184, 1976PubMedCrossRefGoogle Scholar
  97. 97.
    Ward MK, Feest TG, Ellis HA: Osteomalacic dialysis osteodystrophy: evidence for a waterborne etiological agent, probably aluminum. Lancet 1: 841, 1978PubMedGoogle Scholar
  98. 98.
    Hodsman AB, Sherrard DJ, Alfrey AC et al.: Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 54: 539, 1982PubMedGoogle Scholar
  99. 99.
    Maloney NA, Ott SM, Alfrey AC et al.: Histologic quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med 99: 206, 1982PubMedGoogle Scholar
  100. 100.
    Pierce-Myli M, Pierides AM: Iron and aluminum osteomalacia during hemodialysis: anew syndrome. (Abstract) Kidney Int 25: 153, 1984Google Scholar
  101. 101.
    Phelps KR, Vigorita VJ, Bansal M, Einhorn T: Histological demonstration of iron but not aluminum in a case of dialysis associated osteomalacia. Am J Med 84: 775, 1988PubMedGoogle Scholar
  102. 102.
    Cannata JB, Diaz Lopez JB: Insights into the complex aluminium and iron relationship. Nephrol Dial Transplant 6: 605, 1991PubMedGoogle Scholar
  103. 103.
    Boyce BF, Fell GS, Elder H: Hypercalcemic osteomalacia due to aluminum toxicity. Lancet 2: 1009, 1982PubMedGoogle Scholar
  104. 104.
    Hodsman AB, Sherrard DJ, Wong EGC et al.: Vitamin D resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med 94: 629, 1981PubMedGoogle Scholar
  105. 105.
    Llach F: Effects of renal failure and dialysis on divalent ion metabolism. in Divalent Ion Homeostasis, Vol 11, Contemporary Issues in Nephrology, edited by BM Brenner, JH Stein, New York, Churchill, Livingstone, Inc, 1983, p 291Google Scholar
  106. 106.
    Zins B, Zingraff J, Basile C et al.: Tumoral calcifications in hemodialysis patients: possible role of aluminum intoxication. Nephron 60: 260, 1992PubMedGoogle Scholar
  107. 107.
    Sherrard DJ, Ott SM, Andress DL: Pseudohyperparathyroidism: a syndrome associated with aluminum intoxication in chronic renal failure. Am J Med 79: 127, 1985PubMedGoogle Scholar
  108. 108.
    Norris KC, Crooks P, Nebeker HG et al.: Clinical and laboratory features of aluminum related bone disease: differences between sporadic and ‘epidemic’ forms of the syndrome. Am J Kidney Dis 6: 342, 1985PubMedGoogle Scholar
  109. 109.
    Andress DL, Felsenfeld AJ, Voigts A, Llach F: Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. Kidney Int 24: 364, 1983PubMedGoogle Scholar
  110. 110.
    Andress DL, Ott SM, Maloney NA, Sherrard DJ: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312: 468, 1985PubMedCrossRefGoogle Scholar
  111. 111.
    Ellis HA, Peart KM: Azotemic renal osteodystrophy; a quantitative study on iliac. J Clin Pathol 26: 83, 1973PubMedGoogle Scholar
  112. 112.
    Cournot-Witmer G, Zingraff J, Plachott JJ et al.: Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 20: 375, 1981PubMedGoogle Scholar
  113. 113.
    Ellis HA: Aluminum and osteomalacia after parathyroidectomy. Ann Intern Med 96: 533, 1982PubMedGoogle Scholar
  114. 114.
    Ott SM, Andress DL, Nebeker HG et al.: Changes in bone histology after treatment with desferrioxamine. Kidney Int 29(Suppl 18): S108, 1986Google Scholar
  115. 115.
    Fanti P, Faugere MC, Smith AJ, Malluche HH: Removal of aluminum is associated with increased production of 1, 25(OH)2 Vit. D in dialysis patients. (Abstract) Kidney Int 31: 346, 1987Google Scholar
  116. 116.
    Ricanati ES, Ott SM, Klein KL: Evaluation of bone in dialysis patients exposed to aluminum in dialysate. Kidney Int 21: 176, 1982Google Scholar
  117. 117.
    King SW, Savory J, Wills MR: Aluminum distribution in serum following hemodialysis. Ann Clin Lab Sci 12: 143, 1982PubMedGoogle Scholar
  118. 118.
    Mion C, Branger B, Issautier R: Dialysis fracturing osteomalacia without hyperparathyroidism in patients treated with HCO3 rinsed Redy cartridge. Trans Amer Soc Artif Internal Organs 27: 634, 1981Google Scholar
  119. 119.
    Llach F, Gardner PW, George CRP, Cairoli O: Aluminum kinetics using bicarbonate dialysate with the sorbent system. Kidney Int 43: 899, 1993PubMedGoogle Scholar
  120. 120.
    Milliner DS, Shinaberger JH, Shuman P, Coburn JW: Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med 312: 165, 1985PubMedCrossRefGoogle Scholar
  121. 121.
    Klein GL, Ott SM, Alfrey AC et al.: Aluminum as a factor in the bone disease of long-term parenteral nutrition. Trans Assoc Am Physicians 95: 155, 1982PubMedGoogle Scholar
  122. 122.
    Moreno A, Dominguez P, Dominguez C, Ballabriga A: High serum aluminium levels and acute reversible encephalopathy in a 4-year-old boy with acute renal failure. Eur J Ped 150: 513, 1993Google Scholar
  123. 123.
    Berlyne GM, Ben-Ari J, Pest D: Hyperaluminaemia from aluminum resins in chronic renal failure. Lancet 2: 494, 1970PubMedGoogle Scholar
  124. 124.
    Kaehny WD, Hegg AP, Alfrey AC: Gastrointestinal absorption of aluminum from aluminum containing antacids. N Engl J Med 296: 1389, 1977PubMedCrossRefGoogle Scholar
  125. 125.
    Hercz G, Andress DL, Nebeker HG et al.: Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide. Am J Kidney Dis 11: 70, 1988PubMedGoogle Scholar
  126. 126.
    Winney RJ, Cowie JF, Robson JS: The role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney Int 29(Suppl 18): S91, 1986Google Scholar
  127. 127.
    Salusky IB, Coburn JW, Foley J et al.: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108: 767, 1986PubMedGoogle Scholar
  128. 128.
    Robertson JA, Salusky IB, Goodman WG et al.: Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. Ann Intern Med 111: 179, 1989PubMedGoogle Scholar
  129. 129.
    Freundlich M, Zilleruelo G, Abitbol C et al.: Infant formula as a cause of aluminum toxicity in neonatal uremia. Lancet 2: 527, 1985PubMedGoogle Scholar
  130. 130.
    Salusky IB, Coburn JW, Nelson P, Goodman WG: Prospective evaluation of aluminum loading from formula in infants with uremia. J Pediatr 116: 724, 1984Google Scholar
  131. 131.
    Ittel TH, Buddington B, Miller NL, Alfrey AC: Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 32: 821, 1987PubMedGoogle Scholar
  132. 132.
    Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67: 929, 1988PubMedGoogle Scholar
  133. 133.
    Slanina P, Frech W, Ekstrom L et al.: Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 32: 539, 1986PubMedGoogle Scholar
  134. 134.
    Bakir AA, Hryhorczuk DO, Berman E: Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed patients. Trans Am Soc Artif Intern Organs 32: 171, 1986Google Scholar
  135. 135.
    Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17: 708. 1991PubMedGoogle Scholar
  136. 136.
    Sherrard DJ: Aluminum, Much ado about something. N Engl J Med 324: 55, 1991CrossRefGoogle Scholar
  137. 137.
    Czapla K, Rodger RS, Halls DJ et al.: Ranitidine reduces aluminum toxicity in patients with renal failure. Nephrol Dial Transplant 7: 1246, 1992PubMedGoogle Scholar
  138. 138.
    Cannata JB, Fernandez-Soto I, Fernandez-Menendez MJ et al.: Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int 39: 799, 1991PubMedGoogle Scholar
  139. 139.
    Cannata JB, Olaizola IR, Gomez-Alonso C et al.: Serum aluminum transport and aluminum uptake in chronic renal failure: role of iron and aluminum metabolism. Nephron 65: 141, 1993PubMedGoogle Scholar
  140. 140.
    Rosenlof K, Fyhrquist F, Tenhunen R: Erythropoietin, aluminium and anaemia in patients on haemodialysis. Lancet 335: 247, 1990PubMedGoogle Scholar
  141. 141.
    Casati S, Castelnovo C, Campise M, Ponticelli C: Aluminium interference in the treatment with Human erythropoietin. Nephrol Dial Transplant 5: 441, 1990PubMedGoogle Scholar
  142. 142.
    D’Haese PC, De Broe ME: Aluminum toxicity. in Handbook of Dialysis, edited by Daugirdas JT, Ing TS, Boston/New York/Toronto/London, Little, Brown and Company, 1994, p 522Google Scholar
  143. 143.
    Felsenfeld AJ, Harrelson JM, Gutman RA: Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 96: 34, 1984Google Scholar
  144. 144.
    Alvarez-Ude F, Feest TG, Ward MK et al.: Hemodialysis bone disease: Correlation between clinical, histologic and other findings. Kidney Int 14: 68, 1978PubMedGoogle Scholar
  145. 145.
    Andress DL, Hercz G, Kopp JB et al.: Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 2: 525, 1987PubMedGoogle Scholar
  146. 146.
    Cohen-Solal ME, Sebert JL, Boudailliez B et al.: Nonaluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? Bone 13: 1, 1992PubMedGoogle Scholar
  147. 147.
    Pei Y, Hercz G, Greenwood C el al.: Renal osteodystrophy in diabetic patients. Kidney Int 44: 159, 1993PubMedGoogle Scholar
  148. 148.
    Sherrard DJ, Ott S, Maloney N et al.: Renal osteodystrophy: clasification, cause and treatment. in Clinical Disorders of Bone and Mineral Metabolism, edited by Frame, B, Potts, JT Jr, Amsterdam, Excerpta Medica, 1983, p 254Google Scholar
  149. 149.
    Sherrard DJ, Hercz G, Pei Y et al.: The spectrum of bone disease in end-stage renal failure — an evolving disorder. Kidney Int 43: 436, 1993PubMedGoogle Scholar
  150. 150.
    Hercz G, Pei Y, Greenwood C et al.: Aplastic osteodystrophy without aluminum: the role of’ suppressed’ parathyroid function. Kidney Int 44: 860, 1993PubMedGoogle Scholar
  151. 151.
    Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int (Suppl 38): S62, 1992Google Scholar
  152. 152.
    Andress DL, Maloney NA, Endres DB, Sherrard DJ: Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res 1: 391, 1986PubMedGoogle Scholar
  153. 153.
    Rodriguez M, Lorenzo V, Felsenfeld AJ, Llach F: Effect of parathyroidectomy on aluminum toxicity and azotemic bone disease in the rat. J Bone Miner Res 5: 379, 1990PubMedGoogle Scholar
  154. 154.
    Heidbreder E, Gotz R, Schafferhans K, Heidland A: Diminished parathyroid gland responsiveness to hypocalcemia in diabetic patients with uremia. Nephron 42: 285, 1986PubMedGoogle Scholar
  155. 155.
    McNair P, Christensen MS, Madsbad S et al.: Hypoparathyroidism in diabetes mellitus. Acta Endocrinol 96: 81, 1981PubMedGoogle Scholar
  156. 156.
    Salusky IB, Coburn JW, Brill J: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33: 975, 1988PubMedGoogle Scholar
  157. 157.
    Bender FH, Bernardini J, Piraino B: Calcium mass transfer with dialysate containing 1.25 and 1.75 mmol/L calcium in peritoneal dialysis patients. Am J Kidney Dis 20: 367, 1992PubMedGoogle Scholar
  158. 158.
    de Vernejoul MC, Marie P, Kuntz D et al.: Non-osteomalacic osteopathy associated with chronic hypophosphatemia. Calcif Tissue Int 34: 219, 1982PubMedGoogle Scholar
  159. 159.
    Stanbury SW, Lumb GA: Parathyroid function in chronic renal failure: a statistical survey of the plasma biochemistry in azotaemic renal osteodystrophy. Q J Med 35: 1, 1966PubMedGoogle Scholar
  160. 160.
    Mechanic GL et al.: Quantitative changes of bone collagen cross-links and precursors in vitamin D deficiency. Biochem Biophys Res Comm 47: 760, 1972PubMedGoogle Scholar
  161. 161.
    Russell JE, Avioli LV: 25 Hydroxycholecalciferol enhanced bone maturation in the parathyroprivic state. J Clin Invest 56: 792, 1975PubMedGoogle Scholar
  162. 162.
    Russell JE, Termine JD, Avioli LV: Abnormal bone mineral maturation in the chronic uremic state. J Clin Invest 52: 2848, 1973PubMedGoogle Scholar
  163. 163.
    Alfrey AC, Solomons CC: Bone pyrophosphate in uremia and its association with extraosseous calcification. J Clin Invest 57: 700, 1976PubMedGoogle Scholar
  164. 164.
    Termine JD, Posner AS: Amorphous/crystalline interrelationships in bone mineral. Calcif Tissue Resch 1: 8, 1967Google Scholar
  165. 165.
    Kaye M: Magnesium metabolism in the rat with chronic renal failure. J Lab Clin Med 84: 536, 1974PubMedGoogle Scholar
  166. 166.
    Giangrande A, Costantini S, Ballanti P et al.: Bone Mineral and Aluminum concentrations in patients undergoing CAPD. Proc Eur Dialysis Transpl Assoc 1991Google Scholar
  167. 167.
    Pellegrino ED, Biltz RM: The composition of human bone in uremia. Medicine 44: 397, 1965PubMedGoogle Scholar
  168. 168.
    Burnell JM, Teubner E, Wergedal JE, Sherrard DJ: Bone crystal maturation in renal osteodystrophy in humans. J Clin Invest 53: 52, 1974PubMedGoogle Scholar
  169. 169.
    Pellegrino ED, Biltz RM, Letteri JM: Interrelationships of carbonate, phosphate, monohydrogen phosphate, calcium, magnesium and sodium in uraemic bone: comparison of dialyzed and nondialyzed patients. Clin Sci Molec Med 53: 307, 1977Google Scholar
  170. 170.
    Kaye M, Fruch AJ, Silverman M: A study of vertebral bone powder from patients with chronic renal failure. J Clin Invest 49: 442, 1970PubMedGoogle Scholar
  171. 171.
    Stanbury SW, Lumb GA: Metabolic studies of renal osteodystrophy. I. Calcium, phosphorus and nitrogen metabolism in rickets, osteomalacia, and hyperparathyroidism complicating chronic uremia and in the osteomalacia of the adult Fanconi syndrome. Q J Med 35: 1, 1966PubMedGoogle Scholar
  172. 172.
    Barzel US, Jowsey J: The effects of chronic acid and alkali administration on bone turnover in adult rats. Clin Sci 36: 517, 1969PubMedGoogle Scholar
  173. 173.
    Cunningham J, Fraher LJ, Clemens TL et al.: Chronic acidosis with metabolic bone disease. Effect of alkali on bone morphology and vitamin D metabolism. Am J Med 73: 199, 1982PubMedGoogle Scholar
  174. 174.
    Lefebvre A, de Vernejoul MC, Gueris J et al.: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36: 1112, 198Google Scholar
  175. 175.
    Floege J, Schaffer J, Koch KM, Shaldon S: Dialysis related amyloidosis: a disease of chronic retention and inflammation? Kidney Int (Suppl 38): S78, 1992Google Scholar
  176. 176.
    Koch KM: Dialysis-related amyloidosis. Kidney Int 41: 16, 1992Google Scholar
  177. 177.
    Wright RS, Mehls O, Ritz E, Coburn JW: Musculoskeletal manifestation of chronic renal failure, dialysis and transplantation. in Renal Manifestations in Rheumatic Disease, edited by Bacon P, Hadler N, London, Butterworth, 1982, p 352Google Scholar
  178. 178.
    Mirahmadi KS, Coburn JW, Bluestone R: Calcific periarthritis and hemodialysis. JAMA 229: 548, 1973Google Scholar
  179. 179.
    Hardouin P, Lecomte-Houcke M, Flipo RM et al.: Current aspects of osteoarticular pathology in patients undergoing hemodialysis: study of 80 patients. Part 2. Laboratory and pathologic analysis. Discussion of the pathogenic mechanism. J Rheumatol 14: 784, 1987PubMedGoogle Scholar
  180. 180.
    Massry SG et al.: Abnormalities of the musculoskeletal system in hemodialysis patients. Semin Arthritis Rheum 4: 321, 1975PubMedGoogle Scholar
  181. 181.
    Massry SG, Popovtzer MM, Coburn JW: Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching following subtotal parathyroidectomy. N Engl J Med 279: 697, 1968PubMedCrossRefGoogle Scholar
  182. 182.
    Gilchrest B et al.: Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 297: 136, 1977PubMedCrossRefGoogle Scholar
  183. 183.
    Pederson JA, Matter BJ, Czerwinski A, Llach F: Relief of idiopathic generalized pruritus in dialysis patients with activated oral charcoal. Ann Intern Med 93: 446, 1980PubMedGoogle Scholar
  184. 184.
    De Marchi S et al.: Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326: 969, 1992PubMedCrossRefGoogle Scholar
  185. 185.
    Nielsen T et al.: Pruritus and xerosis in patients with chronic renal failure. Dan Med Bull 27: 269, 1980PubMedGoogle Scholar
  186. 186.
    Stockenhuber F et al.: Increased plasma histamine levels in uraemic pruritus. Clin Sci 79: 477, 1990PubMedGoogle Scholar
  187. 187.
    Berlyne GM: Microcrystalline conjunctival calcification in renal failure: a useful clinical sign. Lancet 2: 366, 1968PubMedGoogle Scholar
  188. 188.
    Berlyne GM, Shaw AG: Red eyes in renal failure. Lancet 1:4, 1967PubMedGoogle Scholar
  189. 189.
    Schott GD, Wills MR: Muscle weakness in osteomalacia. Lancet 1: 626, 1976PubMedGoogle Scholar
  190. 190.
    Baker LRI, Ackrill P, Cattell WR: Iatrogenic osteomalacia and myopathy due to phosphate depletion. Br Med J 3: 150, 1974PubMedGoogle Scholar
  191. 191.
    Smith R, Stern G: Myopathy, osteomalacia and hyperparathyroidism. Brain 90: 593, 1967PubMedGoogle Scholar
  192. 192.
    Coburn JW, Nebeker HG, Hercz G et al.: Role of aluminum accumulation in the pathogenesis of renal osteodystrophy, in Nephrology, Vol II, edited by Robinson RR, New York, Springer-Verlag, 1984, p 1383Google Scholar
  193. 193.
    Malette LE, Patten BM, Engel WK: Neuromuscular disease in secondary hyperparathyroidism. Ann Intern Med 82: 474, 1975Google Scholar
  194. 194.
    Brickman AS, Sherrard DJ, Jowsey J: 1,25 dihydroxycholecalciferol: effect on skeletal lesions and plasma parathyroid hormone in uremic osteodystrophy. Arch Intern Med 134: 883, 1974PubMedGoogle Scholar
  195. 195.
    Henderson RG, Russell RGG, Ledingham JG: Effects of 1,25 dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 249: 83, 1974Google Scholar
  196. 196.
    Kanis JA, Cundy T, Earnshaw M et al.: Treatment of renal bone disease with 1α-hydroxylated derivitives of vitamin D3: Clinical, biochemical, radiographic and histological responses. Q J Med (New Series) 48: 289, 1979Google Scholar
  197. 197.
    Cirincione R, Baker B: Tendon rupture with secondary hyperparathyroidism. J Bone Joint Surg 57: 852, 1975PubMedGoogle Scholar
  198. 198.
    Preston F, Adicoff A: Hyperparathyroidism with avulsion of three major tendons. N Engl J Med 266: 968, 1962PubMedCrossRefGoogle Scholar
  199. 199.
    Avioli LV: Collagen metabolism, uremia and bone. Kidney Int 4: 105, 1973PubMedGoogle Scholar
  200. 200.
    Murphy KJ, McPhee I: Tears of major tendons in chronic acidosis with elastosis. J Bone Joint Surg 53: 510, 1971Google Scholar
  201. 201.
    Ryuzaki M, Konishi K, Kasuga A et al.: Spontaneous rupture of the quadriceps tendon in patients on maintenance hemodialysis-repor tof three cases with clinicopathological observations. Clin Nephrol 32: 144, 1989PubMedGoogle Scholar
  202. 202.
    Kurer MH, Baillod RA, Madgwick JC: Musculoskeletal manifestations of amyloidosis. A review of 83 patients on haemodialysis for at least 10 years. J Bone Joint Surg 73:271, 1991Google Scholar
  203. 203.
    Gipstein R, Coburn JW, Adams D et al.: Calciphylaxis in man: A syndrome of tissue necrosis and vascular calcification. in 11 patients with chronic renal disease. Arch Intern Med 136: 1273, 1976PubMedGoogle Scholar
  204. 204.
    Massry SG, Gordon A, Coburn JW: Vascular calcification and peripheral necrosis in a renal transplant recipient: Reversal of lesion following subtotal parathyroidectomy. Am J Med 49: 416, 1970PubMedGoogle Scholar
  205. 205.
    Weidmann P, Massry SG, Coburn JW: Effect of acute hypercalcemia on blood pressure in patients with chronic renal failure. Ann Intern Med 76: 741, 1972PubMedGoogle Scholar
  206. 206.
    Selye H: Calciphylaxis, Chicago, Univ of Chicago Press, 1982Google Scholar
  207. 207.
    Duh QY, Lim RC, Clark OH: Calciphylaxis in (secondary hyperparathyroidism. Diagnosis and parathyroidectomy. Arch Surg 126: 1213, 1991PubMedGoogle Scholar
  208. 208.
    Poch E, Almirall J, Alsina M et al.: Calciphylaxis in a hemodialysis patient: Appearance after parathyroidectomy during a psoriatic flare. Am J Kidney Dis 19: 285, 1992PubMedGoogle Scholar
  209. 209.
    Mehls O, Ritz E, Krempien B: Roentgenological signs in the skeleton of uremic children. An analysis of the anatomical principles underlying the roentgenological changes. Pediatr Radiol 1: 183, 1973PubMedGoogle Scholar
  210. 210.
    Mehls O: Renal osteodystrophy in children: etiology and clinical aspects. in Endstage Renal Disease in Children, edited by Fine RN, Gruskin AB, Philadelphia, WB Saunders, 1984, p 227Google Scholar
  211. 211.
    Stanbury SW: The role of vitamin D in renal bone disease. Clin Endocrinol 7: 25S, 1977Google Scholar
  212. 212.
    Parfitt AM: Clinical and radiographic manifestations of renal osteodystrophy. in Calcium Metabolism in Renal Failure and Nephrolithiasis, edited by David DS, New York, John Wiley & Sons, 1977, p 150Google Scholar
  213. 213.
    Scharer K et al.: Growth in children with chronic renal failure. Kidney Int 13(Suppl): S68, 1978Google Scholar
  214. 214.
    Chantier C, Donckerwolcke RA, Brunner FP et al.: Combined report on regular dialysis and transplantation of children in Europe. Proc Eur Dial Transplant Assoc 16: 74, 1979Google Scholar
  215. 215.
    Simmons JM, Wilson CJ, Potter DE, Holliday MA: Relation of caloric deficiency to growth failure in children on hemodialysis and the growth response to caloric supplementation. N Engl J Med 285: 653, 1971PubMedCrossRefGoogle Scholar
  216. 216.
    Chantier C, Holliday M: Growth in children with renal disease, with special reference to the effects of caloric malnutrition: a review. ClinNephrol 1: 230, 1973Google Scholar
  217. 217.
    McSherry E, Morris RC: Attainment and maintenance of normal growth status with alkali therapy in infants and children with classic renal tubular acidosis (RTA). J Clin Invest 61: 509, 1978PubMedGoogle Scholar
  218. 218.
    Saenger P, Wiedmann E, Schwartz E: Somatomedin and growth after renal transplantation. Pediatr Res 8: 163, 1974PubMedGoogle Scholar
  219. 219.
    Chesney RW, Moorthy A, Eisman JA et al.: Increased growth after long-term oral 1,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 298: 238, 1978PubMedCrossRefGoogle Scholar
  220. 220.
    Tonshoff B, Mehls O, Heinrich U et al.: Growthstimulating effect of recombinant human growth hormone in children with end-stage renal disease. J Pediatrics 116: 561, 1990Google Scholar
  221. 221.
    Blum WF, Ranke MB, Kietzmann K et al.: Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 5: 539, 1991PubMedGoogle Scholar
  222. 222.
    Eidemak I, Feldt-Rasmussen B, Strandgaard S et al.: Insulin resistance is present in moderate uraemia and correlated to the maximal aerobic work capacity. J Am Soc Nephrol 3: 281, 1992Google Scholar
  223. 223.
    Mehls O, Ritz E, Hunziker EB et al.: Improvement of growth and food utilization by human recombinant growth hormone in uremia. Kidney Int 33: 45, 1988PubMedGoogle Scholar
  224. 224.
    Stivelman JC: Refractoriness to recombinant human epoetin treatment. in Dialysis Therapy, edited by Nissenson AR, Fine RN, Philadelphia, Mosby-Year Book, 1993, p 236Google Scholar
  225. 225.
    Coburn JW, Massry SG, DePalma JS, Shinaberger JH: Rapid appearance of hypercalcemia with initiation of hemodialysis. JAMA 210: 2276, 1969PubMedGoogle Scholar
  226. 226.
    Mazzaferro S, Coen G, Bandini S et al.: Mitral annulus calcification in uremia. Nephrol Dial Transplant 8: 335, 1993PubMedGoogle Scholar
  227. 227.
    Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on heart cells. J Clin Invest 67: 1215, 1981PubMedGoogle Scholar
  228. 228.
    London GM, Fabiani F, Marchais SJ et al.: Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31: 973, 1987PubMedGoogle Scholar
  229. 229.
    London GM, de Vernejoul MC, Fabiani F et al.: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 32: 900, 1987PubMedGoogle Scholar
  230. 230.
    Puschett JB, Moranz J, Kurnick WS: Evidence for a direct action of cholecalciferol and 25 hydroxycholecalciferol on the renal transport of phosphate, sodium and calcium. J Clin Invest 51: 373, 1972PubMedGoogle Scholar
  231. 231.
    Marchais SJ, Guerin AP, London AM et al.: Long-term effects of parathyroidectomy on left ventricular function in hemodialysis patients. Blood Purif 2: 155, 1992Google Scholar
  232. 232.
    Chazan J, Abuelo G, Blonsky S: Plasma aluminum levels (unstimulated and stimulated): clinical and biochemical findings in 185 patients undergoing chronic hemodialysis for 4 to 95 months. Am J Kidney Dis 13: 284, 1989PubMedGoogle Scholar
  233. 233.
    Llach F, Felsenfeld AJ, Coleman M et al.: The natural course of dialysis osteomalacia. Kidney Int 29: S74, 1986Google Scholar
  234. 234.
    Roth A, Nogues C, Galle P et al.: Multiorgan aluminum deposits in a chronic haemodialysis patient. Electron microscope and microprobe studies. Virchows Arch (Pathol Anat) 405: 131, 1984Google Scholar
  235. 235.
    London G, de Vernejoul MC, Fabiani F et al.: Association between aluminum accumulation and cardiac hypertrophy in hemodialyzed patients. Am J Kidney Dis 13: 75, 1989PubMedGoogle Scholar
  236. 236.
    Massry SG, Goldstein D: Role of parathyroid hormone in uremic toxicity. Kidney Int 13(Suppl): S39, 1978Google Scholar
  237. 237.
    Massry SG, Fadda GZ: Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 21: 81, 1993PubMedGoogle Scholar
  238. 238.
    Arieff AI, Massry SG: Calcium metabolism of brain in acute renal failure. J Clin Invest 53: 387, 1974PubMedGoogle Scholar
  239. 239.
    Cooper JD, Lazarowitz V, Arieff AI: Neurodiagnostic abnormalities in patients with acute renal failure. Evidence for neurotoxicity of parathyroid hormone. J Clin Invest 61: 1448, 1978PubMedGoogle Scholar
  240. 240.
    Kiley JE et al.: Evaluation of encephalopathy by EEG frequency analysis in chronic dialysis patients. Clin Nephrol 5: 245, 1976PubMedGoogle Scholar
  241. 241.
    Ball JH et al.: The many facets of secondary hyperparathyroidism. Arch Intern Med 131: 746, 1973PubMedGoogle Scholar
  242. 242.
    Fraser CL, Arieff AI: Nervous system complications in uremia. Ann Intern Med 109: 143, 1988PubMedGoogle Scholar
  243. 243.
    Ni Z, Smogorzewski M, Massry SG: Derangements in acetylcholine metabolism in brain synaptosomes in chronic renal failure. Kidney Int 44: 630, 1993PubMedGoogle Scholar
  244. 244.
    Avram MM et al.: Search for the uremic toxin: Decreased motor nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 298: 1000, 1978PubMedCrossRefGoogle Scholar
  245. 245.
    Arieff AI, Schmidt R: Parathyroid hormone as a uremic neurotoxin. N Engl J Med 299: 362, 1978CrossRefGoogle Scholar
  246. 246.
    Goldstein DA et al.: Effect of parathyroid hormone and uremia on peripheral nerve calcium and motor nerve conduction velocity. J Clin Invest 62: 88, 1978PubMedGoogle Scholar
  247. 247.
    Massry SG, Goldstein DA, Procci W, Kletsky OA: Impotence in patients with uremia: a possible role for parathyroid hormone. Nephron 19: 305, 1977PubMedGoogle Scholar
  248. 248.
    Blumberg A et al.: Influence of 1,25-dihydroxycholecalciferol on sexual dysfunction and related endocrine parameters in patients on maintenance hemodialysis. Clin Nephrol 13: 208, 1980PubMedGoogle Scholar
  249. 249.
    Weinberg SG et al.: Myelofibrosis and renal osteodystrophy. Am J Med 61: 155, 1977Google Scholar
  250. 250.
    Boxer M et al.: Anemia in primary hyperparathyroidism. Arch Intern Med 137: 588. 1977PubMedGoogle Scholar
  251. 251.
    Rao DS et al.: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171, 1993PubMedGoogle Scholar
  252. 252.
    Barbour GL: Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med 139: 889, 1979PubMedGoogle Scholar
  253. 253.
    Meytes D et al.: Effects of parathyroid hormone on erythrocytes. J Clin Invest 67: 1263, 1981PubMedGoogle Scholar
  254. 254.
    Zevin D et al.: Effect of parathyroid hormone and 1,25-dihydroxyvitamin D3 on RNA and heme synthesis by erythroid precursors. Min Electrolyte Metab 6: 125, 1981Google Scholar
  255. 255.
    Bogin E et al.: Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 69: 1017, 1982PubMedGoogle Scholar
  256. 256.
    Remuzzi G et al.: Parathyroid hormone inhibits human platelet function. Lancet 2: 1321, 1981PubMedGoogle Scholar
  257. 257.
    Alexiewicz JM, Gaciong Z, Klinger M et al.: Evidence of impaired T cell function in hemodialysis patients: potential role for secondary hyperparathyroidism. Am J Nephrol 10: 495, 1990PubMedGoogle Scholar
  258. 258.
    Cantin M: Kidney, parathyroid and lipemia. Lab Invest 14: 1691, 1965PubMedGoogle Scholar
  259. 259.
    Perna AF, Fadda GZ, Zhou XJ, Massry SG: Mechanisms of impaired insulin secretion following chronic excess of parathyroid hormone. Am J Physiol 259: F210, 1990PubMedGoogle Scholar
  260. 260.
    Fadda GZ, Thanakitcharu P, Smogorzewski M, Massry SG: Parathyroid hormone raises cytosolic calcium in pancreatic islets: study on mechanisms. Kidney Int 43: 554, 1993PubMedGoogle Scholar
  261. 261.
    Weeke E, Friis TH: Serum fractions of calcium and phosphorus in uremia. Acta Med Scand 189: 79, 1971PubMedCrossRefGoogle Scholar
  262. 262.
    Walton J, Gray TK: Absorption of intestinal phosphate in the human intestine. Clin Sci 56: 407, 1979PubMedGoogle Scholar
  263. 263.
    Walling MW et al.: Jejunal phosphate (Pi) active transport: effects of phosphate depletion and vitamin D. Fed Proc 36: 1097, 1977Google Scholar
  264. 264.
    Walling MW: Intestinal Ca and phosphate transport: differential responses of vitamin D metabolites. Am J Physiol 133: 3488, 1977Google Scholar
  265. 265.
    Coburn JW, Brickman AS, Sherrard DJ: Clinical efficacy of 1,25 dihydroxyvitamin D3 in renal osteodystrophy. in Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism, edited by Norman AW, Schaefer K, Coburn JW, Berlin, de Gruyter, 1977, p 657Google Scholar
  266. 266.
    Gallieni M, Brancaccio D, Padovese P et al., Italian Group for the Study of Intravenous Calcitriol: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42: 1191, 1992PubMedGoogle Scholar
  267. 267.
    Massry SG, Coburn JW, Popovtzer MM: Secondary hyperparathyroidism in chronic renal failure: the clinic spectrum in uremia, during hemodialysis and after renal transplantation. Arch Intern Med 124: 431, 1969PubMedGoogle Scholar
  268. 268.
    Coburn JW, Brickman AS, Massry SG: Medical treatment in primary and secondary hyperparathyroidism. Semin Drug Treat 2: 117, 1972PubMedGoogle Scholar
  269. 269.
    Kopple JD, Coburn JW: Metabolic studies of low protein diets in uremia.II. Calcium, phosphorus and magnesium. Medicine 52: 597, 1973PubMedGoogle Scholar
  270. 270.
    Wiegmann TB, Kaye M: Malabsorption of calcium and phosphate in chronic renal failure: 32P and 45Ca studies in dialysis patients. Clin Nephrol 34: 35, 1990PubMedGoogle Scholar
  271. 271.
    Coburn JW, Popovtzer MM, Massry SG, Kleeman CR: The physiochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med 124: 302, 1969PubMedGoogle Scholar
  272. 272.
    Walser M: The separate effects of hyperparathyroidism, hypercalcemia of malignancy, renal failure and acidosis on the state of calcium phosphate and other ions in plasma. J Clin Invest 41: 1454, 1962PubMedGoogle Scholar
  273. 273.
    Raman A, Chong YK, Sreenevasan G: Effects of varying dialysate calcium concentration on the plasma calcium fractions in patients on dialysis. Nephron 16: 181, 1976PubMedGoogle Scholar
  274. 274.
    Wing AJ, Curtis JR, Eastwood JB: Transient and persistent hypercalcaemia in patients treated by maintenance haemodialysis. Br Med J 4: 150, 1968PubMedGoogle Scholar
  275. 275.
    Messner RP et al.: The effect of hemodialysis, vitamin D, and renal homotransplantation on the calcium malabsorption of chronic renal failure. J Lab Clin Med 74: 472, 1969PubMedGoogle Scholar
  276. 276.
    Morton AR, Hercz G: Hypercalcemia in dialysis patients: comparison of diagnostic methods. Dial Transplant 20: 661, 1991Google Scholar
  277. 277.
    Shimada H, Makamura M, Marumo F: Influence of aluminum on the effect of 1 (OH)D3 on renal osteodystrophy. Nephron 35: 163, 1983PubMedGoogle Scholar
  278. 278.
    Rodriguez M, Felsenfeld AJ, Llach F: The role of aluminum in the development of hypercalcemia in the rat. Kidney Int 31: 766, 1987PubMedGoogle Scholar
  279. 279.
    Slatopolsky E, Weerts C, Lopez-Hilker S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157, 1986PubMedCrossRefGoogle Scholar
  280. 280.
    Schaefer K, Scheer J, Asmus G et al.: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 6: 171, 1991Google Scholar
  281. 281.
    Papadimitriou M, Gingell J, Chisholm G: Hypercalcemia from calcium ion exchange resins in patients on regular hemodialysis. Lancet 2: 948, 1968PubMedGoogle Scholar
  282. 282.
    Koppel MH, Massry SG, Shinaberger JH: Thiazide induced rise in serum calcium and magnesium in patients on maintenance hemodialysis. Ann Intern Med 72: 895, 1970PubMedGoogle Scholar
  283. 283.
    Barbour GL, Coburn JW, Slatopolsky E et al.: Hypercalcemia in an anephric patient with sarcoidosis, evidence for extrarenal generation of 1,25 dihydroxyvitamin D. N Engl J Med 305: 440, 1981PubMedCrossRefGoogle Scholar
  284. 284.
    Felsenfeld AJ, Drezner MK, Llach F: Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch Intern Med 146: 1941, 1986PubMedGoogle Scholar
  285. 285.
    Schmulen AC, Lerman M, Pak CYC et al.: Effect of 1,25-dihydroxyvitamin D3 therapy on jejunal absorption of magnesium in patients with chronic renal failure. Am J Physiol 238: 349G, 1980Google Scholar
  286. 286.
    Coburn JW, Hartenbower DL, Brickman AS: Intestinal absorption of calcium, magnesium, and phosphorus in chronic renal insufficiency. in Calcium Metabolism in Renal Failure and Nephrolithiasis, edited by David DS. New York, John Wiley & Sons, 1977, p 77Google Scholar
  287. 287.
    Brannan PG et al.: Magnesium absorption in the human small intestine: results in patients with absorptive hypercalciuria. J Clin Invest 57: 1412, 1976PubMedGoogle Scholar
  288. 288.
    Alfrey AC, Solomons CC, Ciricillo J, Miller NL: Extraosseous calcification. Evidence for abnormal pyrophosphate metabolism in uremia. J Clin Invest 57: 692, 1976PubMedGoogle Scholar
  289. 289.
    Wallach S: Relation of magnesium to osteoporosis and calcium urolithiasis. Magnesium & Trace Elements 10: 281, 1991Google Scholar
  290. 290.
    Guillot AP, Hood VL, Runge CF, Gennari FJ: The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 30: 114, 1982PubMedGoogle Scholar
  291. 291.
    Stewart WK, Fleming LW: The effects of dialysate magnesium on plasma and erythocyte magnesium and potassium concentrations during maintenance haemodialysis. Nephron 10: 221, 1973Google Scholar
  292. 292.
    Moriniere P, Fournier A, Westeel P et al.: Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Contrib Nephrol 64: 58, 1988PubMedGoogle Scholar
  293. 293.
    O’Donovan R, Baldwin D, Hammer M, Moniz C: Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet i: 880, 1986Google Scholar
  294. 294.
    Freeman RM: The role of magnesium in the pathogenesis of azotemic hypothermia. Proc Soc Exp Biol Med 137: 1069, 1971PubMedGoogle Scholar
  295. 295.
    Freeman RM, Lawton RL, Chamberlain MA: Hard Water syndrome. N Engl J Med 276: 1113, 1967PubMedCrossRefGoogle Scholar
  296. 296.
    Habener JF, Potts JT Jr: Relative effectiveness of magnesium and calcium on the secretion and biosynthesis of parathyroid hormone in vitro. Endocrinology 98: 197, 1976PubMedGoogle Scholar
  297. 297.
    Mennes P, Rosenbaum R, Martin KJ, Slatopolsky E: Hypomagnesemia and impaired parthyroid hormone secretion in chronic renal disease. Ann Intern Med 88: 206, 1978PubMedGoogle Scholar
  298. 298.
    Skillen AW, Pierides AM: Serum alkaline phosphatase isoenzyme patterns in patients with chronic renal failure. Clin Chim Acta 80: 339, 1977PubMedGoogle Scholar
  299. 299.
    Price PA et al.: New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 66: 878, 1980PubMedGoogle Scholar
  300. 300.
    Delmas PD et al.: Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med 102: 470, 1983PubMedGoogle Scholar
  301. 301.
    Slovid DM et al.: Clinical evaluation of bone turnover by serum osteocalcin measurements. Calcif Tissue Int 34: S15, 1982Google Scholar
  302. 302.
    Charhon SA, Delmas PD, Malaval L et al.: Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 63: 892, 1986PubMedGoogle Scholar
  303. 303.
    Epstein S, Traberg H, Raja R et al.: Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60: 1253, 1985PubMedGoogle Scholar
  304. 304.
    Malluche HH et al.: Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26: 869, 1984PubMedGoogle Scholar
  305. 305.
    Coen G, Mazzaferro S, Bonucci E et al.: Bone GLA protein in predialysis chronic renal failure: Effects of 1,25(OH)2D3 administration in a long-term follow-up. Kidney Int 28: 783, 1985PubMedGoogle Scholar
  306. 306.
    Hosoda K, Eguchi H, Nakamoto T et al.: Sandwich immunoassay for intact human osteocalcin. Clin Chem 38: 2233, 1992PubMedGoogle Scholar
  307. 307.
    Saupe J, Konig M, Shearer MJ, Kohlmeier M: Carboxylated osteocalcin concentrations in plasma provide information about two independent bone modulating systems in end stage renal disease (ESRD). J Am Soc Nephrol 3: 676, 1992Google Scholar
  308. 308.
    Coen G, Mazzaferro S, Ballanti P et al.: Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 12: 246, 1992PubMedGoogle Scholar
  309. 309.
    Prockop D, Kivirikko K: Relationship of hydroxyproline excretion in urine to collagen metabolism. Ann Intern Med 66: 1243, 1967Google Scholar
  310. 310.
    Kowalewski J, Tomaszewki J, Hanzlik J: The elimination of free, peptide bound and protein bound hydroxyproline into dialysate during peritoneal dialysis in patients with renal failure. Clin Chim Acta 34: 123, 1971PubMedGoogle Scholar
  311. 311.
    Varghese Z et al.: Plasma hydroxyproline in renal osteodystrophy. Proc Eur Dial Transplant Assoc 10: 187, 1973PubMedGoogle Scholar
  312. 312.
    Hart W et al.: The hydroxyproline content of plasma of patients with impaired renal function. Clin Nephrol 4: 104, 1975PubMedGoogle Scholar
  313. 313.
    Eyre D: New biomarkers of bone resorption. J Clin Endocrinol Metab 74: 470A, 1992PubMedGoogle Scholar
  314. 314.
    Lam KW et al.: Tartrate-resistant (band 5) acid phosphatase activity measured by electrophoresis on acrylamide gel. Clin Chem 24: 309, 1978PubMedGoogle Scholar
  315. 315.
    Kraenzlin M, Lau KHW, Liang L: Development of an immunoassay for human serum osteoclastic tartrateresistant acid phosphatase. J Clin Endocrinol Metab 71: 442, 1990PubMedGoogle Scholar
  316. 316.
    Hamet P et al.: Studies of the elevated extracellular concentration of cyclic AMP in uremic man. J Clin Invest 56: 339, 1975PubMedGoogle Scholar
  317. 317.
    Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 43: 771, 1993PubMedGoogle Scholar
  318. 318.
    Hruska KA, Teitelbaum SL, Kopelman R: The predictability of the histologic features of uremic bone disease by noninvasive techniques. Metab Bone Dis Rel Res 1: 39, 1978Google Scholar
  319. 319.
    Chan YL, Furlong TJ, Cornish CJ, Posen S: Dialysis osteodystrophy. A study involving 94 patients. Medicine (Baltimore) 64: 296, 1985Google Scholar
  320. 320.
    Nussbaum SR, Potts JT Jr: Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism. J Bone Mineral Resch 6(Suppl 2): S43, 1991CrossRefGoogle Scholar
  321. 321.
    Brown RC, Aston JP, Weeks I, Woodhead S: Circulating intact parathyroid hormone measured by a twosite immunochemiluminometric assay. J Clin Endocrinol Metab 65: 407, 1987PubMedGoogle Scholar
  322. 322.
    Morita A, Tabata T, Koyama H et al.: A two-site immunochemiluminometric assay for intact parathyroid hormone and its clinical utility in hemodialysis patients. Clin Nephrol 38: 154, 1992PubMedGoogle Scholar
  323. 323.
    Guillard O, Pineau A, Baruthlo F, Arnaud J: An international quality assessment program for measurement of aluminum in human plasma: a progress report. Clin Chem 34: 1603, 1988PubMedGoogle Scholar
  324. 324.
    Milliner DS, Ott SM, Nebeker HG: Deferoxamine infusion test for diagnosis of aluminum related osteomalacia. Ann Intern Med 101: 775. 1984PubMedGoogle Scholar
  325. 325.
    Piccoli A, Andriani M, Mattiello G et al.: Serum aluminium level in the Veneto chronic haemodialysis population: cross-sectional study on 1,026 patients. Nephron 51: 482, 1989PubMedGoogle Scholar
  326. 326.
    Rovelli E, Luciani L, Pagani C et al.: Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum free fluids. Clin Nephrol 29: 294, 1988PubMedGoogle Scholar
  327. 327.
    Norris KC, Sherrard DJ, Slatopolsky E, Coburn JW: Symptomatic renal bone disease: non-invasive parameters for diagnosis. (Abstract) Abstract Book, XIth Internal Congr Nephrol 405A, 1990Google Scholar
  328. 328.
    Malluche HH, Smith AJ, Abreo L, Faugere MC: The use of desferrioxamine in the management of renal patients with bone aluminum accumulation. N Engl J Med 311: 140, 1984PubMedCrossRefGoogle Scholar
  329. 329.
    de Vernejoul MC, Marchais S, London G: Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation. Am J Kidney Dis 14: 124, 1989PubMedGoogle Scholar
  330. 330.
    Pei Y, Hercz G, Greenwood C et al.: Non-invasive prediction of aluminum bone disease in hemo-and peritoneal dialysis patients. Kidney Int 41: 1374, 1992PubMedGoogle Scholar
  331. 331.
    Mazzaferro S, Coen G, Ballanti P et al.: Deferoxamine test and PTHY serum levels are useful not to recognize but to exclude aluminum-related bone disease. Nephron 61: 151, 1992PubMedGoogle Scholar
  332. 332.
    Yaqoob M, Ahmad R, Roberts N, Helliwell T: Low-dose desferrioxamine test for the diagnosis of aluminum-related bone disease in patients on regular haemodialysis. Nephrol Dial Transplant 6: 484, 1991PubMedGoogle Scholar
  333. 333.
    Subra F, Krari N, Tirot P et al.: Aluminiumdetermination in the skin of patients with and without end-stage renal failure. Nephron 58: 170, 1991PubMedGoogle Scholar
  334. 334.
    Bindi P, Khayat R, Saiag P et al.: There is no aluminum accumulation in the skin of end-stage renal failure patients. Nephron, 1993Google Scholar
  335. 335.
    DiRaimondo CV, Casey T, Stone WJ: Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients. Nephron 43: 22, 1986PubMedGoogle Scholar
  336. 336.
    Gejyo F, Homma N, Suzuki M, Arakawa KM: Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314: 585, 1986PubMedCrossRefGoogle Scholar
  337. 337.
    van Ypersele de Strihou C, Jadoul M, Malghem J, Jamart J, the Working Party on Dialysis Amyloidosis: Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. Kidney Int 39: 1012, 1991PubMedGoogle Scholar
  338. 338.
    Fenves AZ, Emmett M, White MG et al.: Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis 7: 130, 1986PubMedGoogle Scholar
  339. 339.
    Goldstein S, Winston E, Chung TJ et al.: Chronic arthropathy in long term hemodialysis. Am J Med 78: 82, 1985PubMedGoogle Scholar
  340. 340.
    Kuntz D, Naveau B, Bardin T et al.: Destructive spondylarthropathy in hemodialyzed patients. Arthritis Rheum 27: 369, 1984PubMedGoogle Scholar
  341. 341.
    Deforges-Lasseur C, Combe C, Cernier A et al.: Destructive spondyloarthropathy presenting with progressive paraplegia in a dialysis patient. Recovery after surgical spinal cord decompression and parathyroidectomy. Nephrol Dial Transplant 8: 180, 1993PubMedGoogle Scholar
  342. 342.
    Takenaka R, Fukatsu A, Matsuo S et al.: Surgical treatment of hemodialysis-related shoulder arthropathy. Clin Nephrol 38: 224, 1992PubMedGoogle Scholar
  343. 343.
    Gejyo F, Homma N, Hasegawa S. Arakawa M: A new therapeutic approach to dialysis amyloidosis: intensive removal of beta 2-microglobulin with adsorbent column. Artif Organs 17: 240, 1993PubMedCrossRefGoogle Scholar
  344. 344.
    Nelson SR, Sharpstone P, Kingswoood JC: Does dialysis-associated amyloidosis resolve after transplantation? Nephrol Dial Transplant 8: 369, 1993PubMedGoogle Scholar
  345. 345.
    Poznanski AK: Radiologic Evaluation of Bone Mineral in Children in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edited by Favus MJ, New York, Raven Press, 1993, p 115Google Scholar
  346. 346.
    Dent CE, Hodson C: Radiological changes associated with certain metabolic bone diseases. Br J Radiol 27: 605, 1954PubMedGoogle Scholar
  347. 347.
    Meema HE, Rabinovich S, Meema S et al.: Improved radiological diagnosis of azotemic osteodystrophy. Radiology 102: 1, 1972PubMedGoogle Scholar
  348. 348.
    Ritz E, Prager P, Krempien B: Skeletal x-ray findings and bone histology in patients on hemodialysis. Kidney Int 13:316, 1978PubMedGoogle Scholar
  349. 349.
    Meema HE, Oreopoulos DG, Rabinovich S: Periosteal new bone formation (periosteal neostasis) in renal osteodystrophy. Radiology 110: 513, 1974PubMedGoogle Scholar
  350. 350.
    Doyle FH: Radiological patterns of bone disease associated with renal glomerular failure in adults. Br Med Bull 28: 220, 1972PubMedGoogle Scholar
  351. 351.
    Eastwood JB, Bordier PhJ, De Wardener H: Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int 4: 128, 1973PubMedGoogle Scholar
  352. 352.
    Glassford D, Remmers AR, Sarles H: Hyperparathy-roidism in the maintenance dialysis patient. Surg Gynecol Obstet 142: 328, 1976PubMedGoogle Scholar
  353. 353.
    Tatler GL, Baillod RA, Varghese Z et al.: Evolution of bone disease over 10 years in 135 patients with terminal renal failure. Br Med J 4: 315, 1973PubMedGoogle Scholar
  354. 354.
    Prager P, Singer R, Ritz E, Krempien B: Diagnostischer Stellenwert der Lamina dura dentium beim sekundaren Hyperparathyreoidismus. Fortschr Rontgenstrl 129: 237, 1978Google Scholar
  355. 355.
    Meema HE, Meema S: Comparison of microradioscopic and morphometric findings in the hand bones with densitometric finding in the proximal radius in thyrotoxicosis and in renal osteodystrophy. Invest Radiol 7: 88, 1972PubMedGoogle Scholar
  356. 356.
    Ellis K, Hochstim RJ: The skull in hyperparathyroid bone disease. Am J Roentgenol 83: 732, 1960Google Scholar
  357. 357.
    Owen J, Parnell A, Keir M et al.: Critical analysis of the use of skeletal surveys in patients with chronic renal failure. Clin Radiol 39: 578, 1988PubMedGoogle Scholar
  358. 358.
    Chalmers J, Conacher WD, Gardner DL. Scott PJ: Osteomalacia — a common disease in elderly women. J Bone Joint Surg 49B: 403, 1967Google Scholar
  359. 359.
    Ritz E, Krempien B, Mehls O, Malluche HH: Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int 4: 116, 1973PubMedGoogle Scholar
  360. 360.
    Kessler M, Azoulay E, Netter P et al.: Arthropathie du dialyse: resultats d’une etude multicentrique realisee chez 171 malades hemodialyses depuis plus de 10 ans. in Actualites en physiopathologie et pharmacologie articulairs. edited by Gaucher A, Pourel J, Netter P, Kessler M, Paris, Masson, 1989, p 272Google Scholar
  361. 361.
    Norfray J, Calenoff L, DelGreco F, Krumlovsky F: Renal osteodystrophy in patients on hemodialysis as reflected in the bony pelvis. Am J Roentgenol 125: 352, 1975Google Scholar
  362. 362.
    Parfitt AM: Soft tissue calcification in uremia. Arch Intern Med 124: 544, 1969PubMedGoogle Scholar
  363. 363.
    Jonhson C, Graham CB, Curtis FK: Roentgenographic manifestations of chronic renal disease treated by periodic hemodialysis. Am J Radium Ther Nucl Med 101: 915, 1967Google Scholar
  364. 364.
    Benhamou CL, Rouchon JP, Geslin N et al.: Arthropathies des membres chez les insuffisants renaux dialyses. Presse med 16: 119, 1987PubMedGoogle Scholar
  365. 365.
    Chou CT, Wassertein A, Schumacher HR, Fernandez P: Muskuloskeletal manifestations in hemodialysis patients. J Rheumatology 12: 1149, 1985Google Scholar
  366. 366.
    Rubin LA, Farn AG, Rubenstein J et al.: Erosive azotemic osteoarthropathy. Arthritis Rheum 27: 1086, 1984PubMedGoogle Scholar
  367. 367.
    Bardin T, Vasseur M, de Vernejoul MC et al.: Etude prospective de l’atteinte articulair des malades hemodialyses depuis plus de 10 ans. Rev Rheum 55: 131, 1988Google Scholar
  368. 368.
    Meema HE, Oreopoulos DG, Rapoport A: Serum magnesium level and arterial calcification in end stage renal disease. Kidney Int 32: 388, 1987PubMedGoogle Scholar
  369. 369.
    Ritz E, Mehls O, Bommer J: Vascular calcifications under maintenance hemodialysis. Klin Wochenschr 55: 375. 1977PubMedGoogle Scholar
  370. 370.
    Meema HE et al.: Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology 121: 315, 1976PubMedGoogle Scholar
  371. 371.
    DeFrancisco AM, Ellis HA, Owen JP et al.: Parathyroidectomy in chronic renal failure. Q J Med 55: 289, 1985Google Scholar
  372. 372.
    Kainberger F, Traindl O, Baldt M et al.: Renale Osteody-strophie: Spektrum der Rontgensymptomatik bei modernen Formen der Nierentransplantation und Dauerdialy-setherpie. Rofo Fortschr geb Rontgenstr Neuen Bildgeb Verfahr 157: 501, 1992PubMedGoogle Scholar
  373. 373.
    Contiguglia S, Alfrey AC, Miller NL: Nature of soft tissue calcification in uremia. Kidney Int 4: 229, 1973PubMedGoogle Scholar
  374. 374.
    Kuzela D, Huffer WE, Conger JD: Soft tissue calcification in chronic dialysis patients. Am J Pathol 86: 403, 1977PubMedGoogle Scholar
  375. 375.
    Conger JD, Hammond WS, Alfrey AC et al.: Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med 83: 330. 1975PubMedGoogle Scholar
  376. 376.
    Davis B, Poulose K, Reba R: Scanning for uremic pulmonary calcifications. Ann Intern Med 85: 132, 1976PubMedGoogle Scholar
  377. 377.
    Ibels LS, Alfrey AC, Haul L, Huffer WE: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298: 122, 1991CrossRefGoogle Scholar
  378. 378.
    Lumlertgul D, Burke TJ. Gillum D et al.: Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int 29: 658, 1986PubMedGoogle Scholar
  379. 379.
    Barsotti G, Giannoni A, Morelli E et al.: The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 21: 54, 1984PubMedGoogle Scholar
  380. 380.
    Parfitt AM, Massry SG, Winfield A: Osteopenia and fractures occurring during maintenance hemodialysis. A ‘new’ form of renal osteodystrophy. Clin Orthop 87: 287, 1972PubMedGoogle Scholar
  381. 381.
    Homma N, Gejyo F, Kobayashi H et al.: Cystic radiolucencies of carpal bones, distal radius and ulna as a marker for dialysis-associated amyloid osteoarthropathy. Nephron 62: 6, 1992PubMedGoogle Scholar
  382. 382.
    Sole M et al.: Morphological and immunohistochemical findings in dialysis-related amyloidosis. Appl Pathol 7: 350, 1989PubMedGoogle Scholar
  383. 383.
    Zingraff J et al.: β2-microglobulin amyloidosis: esternoclavicualr joint biopsy study in hemodialysis patients. Clin Nephrol 33: 94, 1990PubMedGoogle Scholar
  384. 384.
    Zingraff J, Drueke T: Can the nephrologist prevent dialysis related amyloidosis? Am J Kidney Dis 18: 1, 1991PubMedGoogle Scholar
  385. 385.
    Cobby MJ, Adler RS, Swartz R, Martel W: Dialysis-related amyloid arthropathy: MR findings in four patients. Am J Roentgenol 157: 1023, 1991Google Scholar
  386. 386.
    Kroner G, Stabler A, Seiderer M et al.: Beta 2 microglobulin-related amyloidosis causing atlantoaxial spondyloarthropathy with spinal-cord compression in haemodialysis patients: detection by MRI. Nephrol Dial Transplant 6(Suppl 2): 91, 1991PubMedGoogle Scholar
  387. 387.
    Kay J, Benson CB, Lester S et al.: Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 35: 926, 1992PubMedGoogle Scholar
  388. 388.
    Fleisch H, Russell RGG: Experimental clinical studies with pyrophosphate and diphosphonates. in Calcium Metabolism in Renal Failure and Nephrolithiasis, edited by David DS, New York, John Wiley & Sons, 1977. p 293Google Scholar
  389. 389.
    Rosenthal L, Kaye M: Observations on the mechanism of Tc labeled phosphate complex uptake in metabolic bone disease. Nucl Med 5: 59, 1976Google Scholar
  390. 390.
    Lien JW, Wiegmann TB, Rosenthall L, Kaye M: Abnormal Tc time pyrophosphate bone scans in chronic renal failure. Clin Nephrol 6: 509, 1976PubMedGoogle Scholar
  391. 391.
    Sy W, Mittal A: Bone scan in chronic dialysis patients with evidence of secondary hyperparathyroidism and renal osteodystrophy. Br J Radiol 48: 878, 1975PubMedGoogle Scholar
  392. 392.
    Olgaard K, Heerfordt J, Madsen S: Scintigraphic skeletal changes in uremic patients on regular hemodialysis. Nephron 17:325, 1976PubMedGoogle Scholar
  393. 393.
    Karsenty G, Vigneron N, Jorgetti V: Value of the 99-mTc-methylene diphosphonate bone scan in renal osteodystrophy. Kidney Int 29: 1058, 1986PubMedGoogle Scholar
  394. 394.
    Hodson EM, Howman-Gilles RB, Evans RB et al.: The diagnosis of renal osteodystrophy: a comparison of technitium99 pyrophosphate bone scintography with other techniques. Clin Nephrol 16: 24, 1981PubMedGoogle Scholar
  395. 395.
    de Jonge FA, Pauwels EK, Hamdy NA: Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure. Eur J Nuclear Med 18: 839, 1991Google Scholar
  396. 396.
    Winzelberg GG: Parathyroid imaging. Ann Intern Med 107: 64, 1987PubMedGoogle Scholar
  397. 397.
    Suehiro M, Fukuchi M: Localization of hyperfunctioning parathyroid glands by means of thallium-201 and iodine-131 subtraction scintigraphy in patients with primary and secondary hyperparathyroidism. Ann Nucl Med 6: 185. 1992PubMedCrossRefGoogle Scholar
  398. 398.
    Nisbet AP, Shaw P, Taube D et al.: 51Cr-EDTA/99mTc-MDP ratio: a simple non-invasive method for assessing renal osteodystrophy. Br J Radiol 62: 438, 1989PubMedGoogle Scholar
  399. 399.
    Hawkins PN et al.: Diagnostic radionuclide imaging of amiloid: biological targeting by circulating human serum amyloid P component. Lancet 1: 1413, 1988PubMedGoogle Scholar
  400. 400.
    Floege J et al.: Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-β2-microglobulin. Kidney Int 38: 1169, 1990PubMedGoogle Scholar
  401. 401.
    Gladziwa U, Ittel TH, Dakshinamurty KV et al.: Secondary hyperparathyroidism and sonographic evaluation of parathyroid gland hyperplasia in dialysis patients. Clin Nephrol 38: 162, 1992PubMedGoogle Scholar
  402. 402.
    Fukagawa M, Okazaki R, Takano K et al.: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323: 421, 1990PubMedCrossRefGoogle Scholar
  403. 403.
    Winkelbauer F, Ammann ME, Langle F, Niederle B: Diagnosis of hyperparathyroidism with US after autotransplantation: results of a prospective study. Radiology 186: 255, 1993PubMedGoogle Scholar
  404. 404.
    Jadoul M et al.: Ultrasonography detection of thickened joint capsules and tendons: an early marker of dialysis-related amyloidosis. (Abstract) Nephrol Dial Transplant 5: 727, 1990Google Scholar
  405. 405.
    Nordin BE, MacGregor J, Smith DA: The incidence of osteoporosis in normal women: Its relation to age and menopause. Q J Med 15: 25, 1966Google Scholar
  406. 406.
    Garn S, Poznanski A, Nagy M: Bone measurement in the differential diagnosis of osteopenia and osteoporosis. Radiology 100: 509, 1971PubMedGoogle Scholar
  407. 407.
    Gryfe CI et al.: Determination of the amount of bone in the metacarpal. Age Ageing 1: 213, 1972PubMedGoogle Scholar
  408. 408.
    Parfitt AM: The actions of parathyroid hormone on bone: relation to bone remodeling and turnover calcium homeostasis and metabolic bone disease. Metabolism 25: 909, 1976PubMedGoogle Scholar
  409. 409.
    Bone JM, Davison AM, Robson JS: Role of dialysate calcium concentration in osteoporosis in patients on hemodialysis. Lancet 1: 1047, 1972PubMedGoogle Scholar
  410. 410.
    Sugisaki H, Yamada K, Kataoka H, Kunitomo T: Longterm observation on renal osteodystrophy related parameters in dialysis patients. Nephrol Dial Transplant 6(Suppl 2): 244, 1991Google Scholar
  411. 411.
    Rickers H, Christensen M, Podbro P: Bone mineral content in patients on prolonged maintenance hemodialysis: a three year follow-up study. Clin Nephrol 20: 302. 1983PubMedGoogle Scholar
  412. 412.
    Cameron JR, Mazess RB, Sorenson JA: Precision and accuracy of bone mineral determination by direct photon absorptiometry. Invest Radiol 3: 9, 1968Google Scholar
  413. 413.
    Hahn TJ, Hahn B: Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy. Semin Arthritis Rheum 6: 165, 1976PubMedGoogle Scholar
  414. 414.
    Griffiths HJ. Zimmerman RE, Bailey G, Snider R: The use of photon absorptiometry in the diagnosis of renal osteodystrophy. Radiology 109: 277, 1973PubMedGoogle Scholar
  415. 415.
    Griffiths HJ et al.: The long-term follow-up of 195 patients with renal failure: a preliminary report. Radiology 122: 643, 1977PubMedGoogle Scholar
  416. 416.
    Mazess RB, Peppier W, Chesnut C: Total body mineral and lead body mass by dual photon absorptiometry. Calcif Tissue Int 33: 361, 1981PubMedGoogle Scholar
  417. 417.
    Zanchetta J, Bogado: Bone mineral content in renal transplant patients. Renal bone disease parathyroid hormone and Vitamin D Singapore 92, 1990Google Scholar
  418. 418.
    Denney JD, Sherrard DJ, Nelp WR: Total body calcium and long term calcium balance in chronic renal disease. J Lab Clin Med 82: 226, 1973PubMedGoogle Scholar
  419. 419.
    Cann CE, Genant HK, Ettinger B, Gordan G: Spinal mineral losses in oophorectomized women. JAMA 244: 2056, 1980PubMedGoogle Scholar
  420. 420.
    Funke M, Maurer J, Grabbe E, Scheler F: Vergleichende Untersuchungen mit der quantitativen computertomographie und der Dual-Energy-X-Ray-Absortiometrie zur Knochendichte bei renaler osteopathie. Rofo Fortschr geb Rontgenstr Neuen Bildgeb Verfahr 157: 145, 1992PubMedGoogle Scholar
  421. 421.
    Gagne ER, Urena P, Leite-Silva S et al.: Short-and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 3: 1008, 1992PubMedGoogle Scholar
  422. 422.
    Davies DR, Dent CE, Watson L: Tertiary hyperparathy-roidism. Br Med J iii: 395, 1968Google Scholar
  423. 423.
    Black WC, Slatopolsky E, Elkan J, Hoffsten P: Parathyroid morphology in suppressible and non-suppressible renal hyperparathyroidism. Lab Invest 23: 497, 1970PubMedGoogle Scholar
  424. 424.
    Geffriaud C, Allinne E, Page B et al.: Decrease of tumor-like calcification in uremia despite aggravation of secondary hyperparathyroidism: a case report. Clin Nephrol 38: 158, 1992PubMedGoogle Scholar
  425. 425.
    Massry SG, Kopple JD: Requirements for calcium, phosphorus, and vitamin D. in Nutrition and the Kidney, edited by Mitch WE, Klahr S, Boston/New York/Toronto/London, Little Brown and Company, 1993, p 96Google Scholar
  426. 426.
    Coburn JW, Salusky IB: Control of serum phosphorus in uremia. N Engl J Med 320: 11402, 1989CrossRefGoogle Scholar
  427. 427.
    Lafage M-H, Combe C, Fournier A, Aparicio M: Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42: 1217, 1992PubMedGoogle Scholar
  428. 428.
    Schoenfeld P, Henry R, Laird N: Assessment of nutritional status of the National Cooperative Dialysis Study population. Kidney Int 23: 580, 1980Google Scholar
  429. 429.
    Blumenkrantz MJ, Kopple JD, Moran J, Coburn JW: Metabolic balance studies and dietary protein requirements in patients undergoing continuous peritoneal dialysis. Kidney Int 21: 849, 1982PubMedGoogle Scholar
  430. 430.
    Llach F, Nikakhtar B: Current advances in the therapy of secondary hyperparathyroidism and osteitis fibrosa. Miner Electrolyte Metab 17: 250, 1991PubMedGoogle Scholar
  431. 431.
    Sedman AB, Klein GL, Merritt RJ et al.: Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med 312: 1337, 1985PubMedCrossRefGoogle Scholar
  432. 432.
    Salusky IB, Foley J, Nelson P, Goodman WG: Aluminum accumulation from recommended doses of aluminum hydroxide in dialyzed children. N Engl J Med 324: 527, 1991PubMedCrossRefGoogle Scholar
  433. 433.
    Jenkins DA, Gouldesbrough D, Smith GD et al.: Can low-dosage aluminum hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant 4: 51, 1989PubMedGoogle Scholar
  434. 434.
    Harter HR, Laird NM, Teehan BP: Effects of dialysis prescription on bone and mineral metabolism: The National Cooperative Dialysis Study. Kidney Int 23(Suppl 13): S73, 1983Google Scholar
  435. 435.
    Rutherford E, Mercado A, Hruska KA: An evaluation of a new and effective phosphous binding agent. Trans Amer Soc Artif Internal Organs 19: 446, 1973Google Scholar
  436. 436.
    Clarkson EM, Eastwood JB, Koutsaimanis K, De Wardener H: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 3: 258, 1973PubMedGoogle Scholar
  437. 437.
    Slatopolsky E, Weerts C, Norwood K et al.: Long term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36: 897, 1989PubMedGoogle Scholar
  438. 438.
    Malberti F, Surian M, Poggio F et al.: Efficacy and safety of long term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis 12: 487, 1988PubMedGoogle Scholar
  439. 439.
    Moriniere PG, Boudailliez B, Hocine C et al.: Prevention of osteitis fibrosa, aluminum bone disease and soft-tissue calcification in dialysis patients: a long term comparison of moderate doses of oral calcium ± Mg(OH)3 vs A1(OH)3 ± 1 alpha vitamin D3. Nephrol Dial transplant 4: 1045, 1989PubMedGoogle Scholar
  440. 440.
    Renaud H, Atik A, Herve M et al.: Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: Lack of influence of calcium carbonate. Nephron 48: 28, 1988PubMedGoogle Scholar
  441. 441.
    Sawyer N, Noonan K, Altmann P et al.: High dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminum avoidance in haemodialysis patients. Nephrol Dial Transplant 4: 105, 1989PubMedGoogle Scholar
  442. 442.
    Argiles A, Kerr PG, Canaud B et al.: Calcium kinetics and the long-term effects of lowering dialysale calcium concentration. Kidney Int 43: 630, 1993PubMedGoogle Scholar
  443. 443.
    Sawyer N, Noonan K, Altmann P et al.: High dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminum avoidance in haemodialysis patients. Nephrol Dial Transplant 3: 1, 1988Google Scholar
  444. 444.
    Cunningham J, Beer J, Coldwell RD et al.: Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alphacalcidol. Nephrol Dialysis Transplant 7:63, 1992Google Scholar
  445. 445.
    Fournier A, Moriniere P, Sebert JL et al.: Calcium carbonate, an aluminum free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism. Kidney Int 29(Suppl 18): S114, 1986Google Scholar
  446. 446.
    Clarkson EM, Luck VA, Hynson WV: The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentration and the aluminum content of bone in patients with chronic renal failure. Clin Sci 43: 519, 1972PubMedGoogle Scholar
  447. 447.
    Mai M, Emmett M, Sheikh M et al.: Calcium acetate, an efective phosphorus binder in patients with renal failure. Kidney Int 36: 690, 1989PubMedGoogle Scholar
  448. 448.
    Sheikh M, Maguire J, Emmett M et al.: Reduction of Dietary Phosphorus Absorption by Phosphorus Binders. J Clin Invest 83: 66, 1989PubMedGoogle Scholar
  449. 449.
    Schiller L, Santa Ana CA, Sheikh M et al.: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320: 1110, 1989PubMedCrossRefGoogle Scholar
  450. 450.
    Delmez JA, Tindira CA, Windus DW et al.: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3: 96, 1992PubMedGoogle Scholar
  451. 451.
    Hercz G, Kraut JA, Andress DL: Use of calcium carbonate as a phosphate binder in dialysis patients. Mineral Electrolyte Metab 12: 314, 1986Google Scholar
  452. 452.
    Kobrin SM, Goldstein SJ, Shangraw RF, Raja RM: Variable efficacy of calcium carbonate tablets. Am J Kidney Dis 14: 461, 1989PubMedGoogle Scholar
  453. 453.
    Cushner HM, Copley J, Lindberg J, Foulks C: Calcium citrate, a non aluminum containing phosphate binding agent for treatment of CRF. Kidney Int 35: 95, 1988Google Scholar
  454. 454.
    Oe PL, Lips P, van der Muelen J et al.: Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 28: 180, 1987PubMedGoogle Scholar
  455. 455.
    Moriniere P, Maurouard C, Boudailliez B et al.: Prevention of hyperparathyroidism in patients on maintenance hemodialysis by intravenous 1 alpha hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3±Mg(OH)2. Nephron 60: 154, 1992Google Scholar
  456. 456.
    Schneider HW, Kulbe KD, Weber H, Streicher E: In vitro and in vivo studies with a non-aluminum phosphate-binding compound. Kidney Int 29(Suppl 18): S120, 1986Google Scholar
  457. 457.
    Mahoney J, Hayes J, Ingham J, Posen S: Hypophos-phataemic osteomalacia in patients receiving hemodialysis. Br Med J 2: 142, 1976Google Scholar
  458. 458.
    Kaye M, Turner M, Ardila M et al.: Aluminum and phosphate. Kidney Int 33(Suppl 24): S172, 1988Google Scholar
  459. 459.
    Hou SH, Zhao J, Ellman CF et al.: Calcium and phosphorus fluxes during hemodialysis with a low calcium dialysate. Am J Kidney Dis 18: 217, 1991PubMedGoogle Scholar
  460. 460.
    Albertini BV, Miller JH, Gardner PW, Shinaberger JH: High flux hemodiafiltration: under six hours/week treatment. Trans Amer Soc Artif Internal Organs 30: 227, 1984Google Scholar
  461. 461.
    Albertini BV, Miller JH, Gardner PW, Shinaberger JH: Performance characteristics of the hemoflow F60 in highflux hemodiafiltration. Contrib Nephrol 46: 169, 1985Google Scholar
  462. 462.
    Shinaberger JH, Miller JH, Gardner PW: Characteristics of available dialyzers. edited by Nissenson AR, Fine RN, Genile D, Norwalk, Appleton Century Crofts, 1984Google Scholar
  463. 463.
    Delmez JA, Slatopolsky E, Martin KJ et al.: Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21: 862, 1982PubMedGoogle Scholar
  464. 464.
    Jaffe P, Podenphant J, Heaf JG: Bone histology in CAPD patients: a comparison with hemodialysis and conservatively treated chronic uremics. Adv Perit Dial 5: 171, 1989Google Scholar
  465. 465.
    Cannata JB, Briggs JD, Fell GS, Junor BJR: Comparison of control serum phosphate levels during continuous ambulatory peritoneal dialysis and during hemodialysis. Perit Dial Bull 3: 97, 1983Google Scholar
  466. 466.
    Fleming LW, Hudson SW, Stewart WK: Improved phosphate clearances with polycarbonate membranes. Clin Exp Dialysis Apheresis 6: 211, 1982Google Scholar
  467. 467.
    Miller JH, Gardner PW, Heinekin F et al.: Studies of inorganic phosphate removal during acetate and bicarbonate dialysis. Proc Am Soc Artif Int Organs 12: 57, 1983Google Scholar
  468. 468.
    Llach F, Nikakhtar B: Methods of controlling hyperphos-phatemia in patients with chronic renal failure. Current Opinion Nephrol Hypert 2: 365, 1993CrossRefGoogle Scholar
  469. 469.
    Clarkson EM, McDonald SJ, De Wardener H: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 30: 425. 1966PubMedGoogle Scholar
  470. 470.
    Malluche HH, Werner E, Ritz E: Intestinal absorption of calcium and whole body calcium retention in incipient and advanced renal failure. Mineral Electrolyte Metab 1: 264, 1978Google Scholar
  471. 471.
    Makoff DL, Gordon A, Franklin SS et al.: Chronic calcium carbonate therapy in uremia. Arch Intern Med 123: 15, 1969PubMedGoogle Scholar
  472. 472.
    Curtis JR. De Wardener H, Gower P, Eastwood JB: The use of calcium carbonate and calcium phosphate without vitamin D in the management of renal osteodystrophy. Proc Eur Dial Transplant Assoc 7: 141, 1970Google Scholar
  473. 473.
    Eastwood JB, Bordier PhJ, De Wardener H: Comparison of the effect of vitamin D and calcium carbonate in renal osteomalacia. Quart J Med 40: 569, 1971PubMedGoogle Scholar
  474. 474.
    Ginsberg DS et al.: Hypercalcemia after oral calcium carbonate therapy in patients on chronic hemodialysis. Lancet 1: 1271, 1973Google Scholar
  475. 475.
    Somerville PJ, Kaye M: Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Kidney Int 14: 245, 1978PubMedGoogle Scholar
  476. 476.
    Chanard J et al.: Rapid method for measurement of fractional intestinal absorption of calcium. J Nucl Med 15: 369, 1974Google Scholar
  477. 477.
    Katz A, Hampers CL, Merrill J: Secondary hyperparathy-roidism and renal osteodystrophy in chronic renal failure. Medicine 48: 333, 1969PubMedGoogle Scholar
  478. 478.
    E Fernandez, J Montoliu: Succesful treatment of massive uraenic tumoral calcinosis with daily hemodialysis and very low calcium dialysate. Nephrol Dial Transplant 9: 1207, 1994PubMedGoogle Scholar
  479. 479.
    Lang RM, Fellner SK, Neumann A, Bushinsky DA: Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 108: 424, 1988Google Scholar
  480. 480.
    Llach F, Coburn JW: Renal osteodystrophy and maintenance dialysis. in Replacement of Renal Function by Dialysis, edited by Maher JF, Dordrecht/Boston/Lancaster. Kluwer Academic Publishers, 1989, p 911Google Scholar
  481. 481.
    Regan RJ, Peacock M, Rosen SM: Effect of dialysate calcium concentration on bone disease in patients on hemodialysis. Kidney Int 10: 246, 1976PubMedGoogle Scholar
  482. 482.
    Catto GRD et al.: Haemodialysis therapy and changes in skeletal calcium. Lancet 1: 1150, 1973PubMedGoogle Scholar
  483. 483.
    Coburn JW: Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int 43(Suppl 40): S92, 1993Google Scholar
  484. 484.
    Voigts A, Felsenfeld AJ, Llach F: The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, hydroxyvitamin D and 24,25 dihydroxyvitamin D. Arch Intern Med 142: 1205, 1983Google Scholar
  485. 485.
    Voigts A et al.: The effects of calciferol and its metabolites on patients with chronic renal failure. I. Calciferol, dihydrotachysterol and calcifediol. Arch Intern Med 143: 960, 1983PubMedGoogle Scholar
  486. 486.
    Kaye M et al.: Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis. Ann Intern Med 73: 225, 1970PubMedGoogle Scholar
  487. 487.
    Witmer G, Margolis A, Fontaine O: Effects of 25 hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 10: 395, 1976PubMedGoogle Scholar
  488. 488.
    Peacock M: The clinical uses of 1α-hydroxyvitamin D3. Clin Endocrinol 7(Suppl): 1S, 1977Google Scholar
  489. 489.
    Dent CE, Harper CN, Philpot G: Treatment of renal glomerular osteodystrophy. Q J Med 30: 1, 1961PubMedGoogle Scholar
  490. 490.
    DeLuca HF, Avioli LV: Treatment of renal osteodystrophy with 25-hydroxycholecalciferol. Arch Intern Med 126: 896, 1970PubMedGoogle Scholar
  491. 491.
    Teitelbaum SL, Bone JM, Stein PM: Calcifedol in chronic renal insufficiency: skeletal response. JAMA 235: 164, 1976PubMedGoogle Scholar
  492. 492.
    Fournier A et al.: 1α-Hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease. Proc Eur Dial Transplant Assoc 12: 227, 1976PubMedGoogle Scholar
  493. 493.
    Recker R, Schoenfeld P, Letteri JM et al.: The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 138: 857, 1978PubMedGoogle Scholar
  494. 494.
    Berl T et al.: 1,25 Dihydroxycholecalciferol effects in chronic dialysis. A double-blind-controlled study. Ann Intern Med 88: 774, 1978PubMedGoogle Scholar
  495. 495.
    Eastwood JB, Phillips ME, De Wardener H: Biochemical and histological effects of 1,25-dihydroxycholecalciferol in the osteomalacia of chronic renal failure. in Vitamin D and Problems Related to Uremic Bone Disease, edited by Norman AW, Schaefer K, Grigoleit H-G, v Herrath D, Ritz E, Berlin, de Gruyter, 1975, p 595Google Scholar
  496. 496.
    Sherrard DJ, Brickman AS, Coburn JW: Skeletal response to treatment with 1.25 dihydroxyvitamin D in renal failure. Contrib Nephrol 18: 92, 1980PubMedGoogle Scholar
  497. 497.
    Maxwell D et al.: Calcitriol in dialysis patients. Clin Pharmacol Therap 23: 515, 1978Google Scholar
  498. 498.
    Memmos D et al.: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J 282: 1919, 1981Google Scholar
  499. 499.
    Coburn JW et al.: Prospective, double blind trial with calcitriol in the prophylaxis of bone disease in asymptomatic dialysis patients. in Vitamin D: Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism, edited by Norman AW et al., Berlin, Walterde Gruyter, 1982, p 833Google Scholar
  500. 500.
    Chesney RW, Hamstra A, Jax DK: Influence of long term oral 1,25 dihydroxzyvitamin D in childhood renal osteodystrophy. Contrib Nephrol 18: 55. 1980PubMedGoogle Scholar
  501. 501.
    Seidel A, Herrmann P, Klaus G et al.: Kinetics of serum 1,84 iPTH after high dose calcitriol in uremic patients. Clin Nephrol 39: 210, 1993PubMedGoogle Scholar
  502. 502.
    Massry SG et al.: Use of 1,25(OH)2D3 in the treatment of renal osteodystrophy in patients with moderate renal failure. in Clinical Disorders of Bone and Mineral Metabolism, edited by Frame B, Potts JT Jr, Amsterdam, Excerpta Medica, 1983, p 260Google Scholar
  503. 503.
    Goodman WG, Coburn JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43: 227, 1992PubMedGoogle Scholar
  504. 504.
    Bertoli M, Luisetto G, Ruffatti A et al.: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33: 98, 1990PubMedGoogle Scholar
  505. 505.
    Oettinger CW, Oliver JC, Macon EJ: The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic dialysis patients. J Am Soc Nephrol 3: 995, 1992PubMedGoogle Scholar
  506. 506.
    Norris KC, Kraut JA, Andress DL: Intravenous calcitriol for severe secondary hyperparathyroidism In dialysis patients. Kidney Int 27: 158, 1985Google Scholar
  507. 507.
    Andress DL, Norris KC, Coburn JW et al.: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274, 1989PubMedCrossRefGoogle Scholar
  508. 508.
    Hamdy NAT, Brown C, Kanis JA: Intravenous calcitriol lowers serum calcium concentrations iin uraemic patients with severe hyperparathyroidism and hypercalcemia. Nephrol Dial Transplant 4: 545, 1989PubMedGoogle Scholar
  509. 509.
    Dressler R, Laut J, Lynn RI, Ginsberg N: Intravenous calcitriol for secondary hyperparathyroidism In patients with end-stage renal disease. Clin Nephrol 1995. In pressGoogle Scholar
  510. 510.
    Klaus G, Mehls O, Hinderer J, Ritz E: Is intemfiittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 337: 800. 1991PubMedGoogle Scholar
  511. 511.
    Muramoto H, Haruki K, Yoshimura A et al.: Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of l,25(OH)2VitaminD3. Nephron 58: 288, 1991PubMedGoogle Scholar
  512. 512.
    Martin KJ, Bullal HS, Domoto DT et al.: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 19: 540. 1992PubMedGoogle Scholar
  513. 513.
    Tsukamoto Y, Nomura M, Takahashi Y et al.: The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyperparathroidism. Nephron 57: 23, 1991PubMedGoogle Scholar
  514. 514.
    Reichel H, Szabo A, Uhl J et al.: Intermittent versus continuous administration of 1,25(OH)2D3 in experimental renal hyperparathyroidism. Kidney Int 44: 1259, 1993PubMedGoogle Scholar
  515. 515.
    Delmez JA, Dougan CS, Gearing BK et al.: The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31: 795, 1987PubMedGoogle Scholar
  516. 516.
    Rolla D, Paoletti E, Marsano L et al.: Subcutaneous calcitriol in CAPD patients. Perit Dial Int 13: 118, 1993PubMedGoogle Scholar
  517. 517.
    Campistol JM, Torregrosa JV, Montesinos M et al.: Effectiveness of subcutaneous calcitriol (sCa) in the treatment of secondary hyperparathyroidism (HPT). J Am Soc Nephrol 4: 718, 1993Google Scholar
  518. 518.
    Brickman AS et al.: Comparison of effects of 1-α-hydroxyvitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest 57: 1540, 1976PubMedGoogle Scholar
  519. 519.
    Coburn JW, Brickman AS, Sherrard DJ: Use of l,25(OH)2vitamin D3 to separate ‘types’ of renal osteodystrophy. Proc Eur Dial Transplant Assoc 14: 442, 1977PubMedGoogle Scholar
  520. 520.
    Davison AM, Peacock M, Walker GS et al.: Phosphate and 1-alpha-hydroxyvitamin D3 therapy in haemodialysis patients. Clin Endocrinol 7(Suppl): 91S, 1977Google Scholar
  521. 521.
    Brandi L, Daugaard H, Tvedegaard E et al.: Effects of intravenous 1α(OH)D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 53: 294, 1989Google Scholar
  522. 522.
    Lind L, Wengle B, Wide L et al.: Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. Nephron 48: 296, 1988PubMedGoogle Scholar
  523. 523.
    Ljunghall S, Althoff P, Fellstrom B et al.: Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 53: 194, 1989Google Scholar
  524. 524.
    Brandi L, Daugaard H, Tvedegaard E et al.: Long-term suppression of secondary hyperparathyroidism by intravenous 1α-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 12: 311, 1992PubMedGoogle Scholar
  525. 525.
    Pierides AM, Ellis HA, Ward MK: Barbiturate and anti-convulsant treatment in relation to osteomalacia with haemodialysis and renal transplantation. Br Med J 1: 190, 1976PubMedGoogle Scholar
  526. 526.
    Pierides AM, Kerr DNS, Ellis HA: 1α — hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy. Clin Nephrol 5: 189, 1976Google Scholar
  527. 527.
    Rutherford WE et al.: The effect of 5,6-trans vitamin D3 on calcium absorptin in chronic renal disease. J Clin Endocrinol Metab 40: 13, 1975PubMedCrossRefGoogle Scholar
  528. 528.
    Hodsman J, Wong EG, Sherrard DJ: Preliminary trials with 24,25 dihydroxyvitamin D3 in dialysis osteomalacia. Am J Med 74: 407, 1983PubMedGoogle Scholar
  529. 529.
    Ott SM, Recker R, Coburn JW, Sherrard DJ: Vitamin D therapy in aluminum related osteomalacia. Kidney Int 32: 107, 1983Google Scholar
  530. 530.
    Canterbury JM et al.: Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest 61: 1375, 1977Google Scholar
  531. 531.
    Friedlander MA, Horst RL, Hawker CC: Absence of effect of 24,25 dihydroxycholecalciferol on serum immunoreactive PTH in patients with persistent hyper-parathyroidism after renal transplantation. Clin Nephrol 22: 206, 1984PubMedGoogle Scholar
  532. 532.
    Olgaard K, Finco D, Schwartz J: Effect of 24,25 dihydroxy-vitamin D3 on PTH levels and bone histology in dogs with chronic uremia. Kidney Int 25: 791, 1984Google Scholar
  533. 533.
    Dunstan CR et al.: Treatment of hemodialysis bone disease with 24,25(OH)2D3 and 1,25(OH)2D3 alone or in combination. Mineral Electrolyte Metab 11: 358, 1985Google Scholar
  534. 534.
    Popovtzer MM, Levi J, Bar-Khayim Y et al. Assessment of combined 24,25(OH)2D3 and 1 alpha (0H)D3 therapy for bone disease in dialysis patients. Bone 13: 369, 1992PubMedGoogle Scholar
  535. 535.
    Brown AJ, Ritter CR, Finch JL et al.: The noncalcemic analogue of vitamin D, 22 oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 279, 1989Google Scholar
  536. 536.
    Brown AJ, Finch JL, Lopez-Hilker S et al.: New active analogues of vitamin D with low calcemic activity. Kidney Int 29(Suppl 29): S22, 1990Google Scholar
  537. 537.
    Slatopolsky E, Berkoben M, Kelber J et al.: Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Supplement 38: S43, 1992Google Scholar
  538. 538.
    Kubrusly M, Gagne E-R, Urena P et al.: Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 44: 551, 1993PubMedGoogle Scholar
  539. 539.
    Kanis JA, Russell RGG: Rate of reversal of hypercalcemia and hypercalciuria induced by vitamin D and its lahydroxylated derivatives. Br Med J 1: 78, 1977PubMedGoogle Scholar
  540. 540.
    Schaefer K, Umlauf E, von Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 19: 460, 1992PubMedGoogle Scholar
  541. 541.
    Coburn JW et al.: Intestinal phosphate absorption in normal and uremic man: effects of 1,25(OH)2 vitamin D3 and 1(OH) vitamin D3. in Phosphate metabolism, edited by Massry SG, Ritz E, New York, Plenum Press, 1993Google Scholar
  542. 542.
    Szabo A, Merke J, Beier E et al.: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049, 1989PubMedGoogle Scholar
  543. 543.
    Fukagawa M, Wi H, Kurokawa K: Calcitriol induces apoptosis of hyperplastic parathyroid cells in uremia. J Am Soc Nephrol 2: 635, 1991Google Scholar
  544. 544.
    Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 39: 874, 1991PubMedGoogle Scholar
  545. 545.
    Tominaga Y, Tanaka Y, Sato K et al.: Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. W J Surg 16: 595, 1992Google Scholar
  546. 546.
    Kitaoka M, Fukagawa M, Tanaka Y et al.: Parathyroid gland size is critical for longterm prognosis of calcitriol pulse therapy in chronic dialysis patients. (Abstract) J Am Soc Nephrol 2: 637, 1991Google Scholar
  547. 547.
    Mallick N, Berlyne G: Arterial calcification after vitamin D therapy in hyperphosphatemic renal failure. Lancet 2: 1316, 1968PubMedGoogle Scholar
  548. 548.
    Stanbury SW, Lumb GA, Nicholson WF: Elective subtotal parathyroidectomy for renal hyperparathyroidism. Lancet 1: 793, 1960PubMedGoogle Scholar
  549. 549.
    Llach F: Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int 38: S62, 1990Google Scholar
  550. 550.
    Kaye M, Rosenthall L, Hill RO, Tabah RJ: Long-term outcome following total parathyroidectomy in patients with chronic renal disease. (Abstract) Clin Nephrol 39: 192, 1993PubMedGoogle Scholar
  551. 551.
    Baumann DS, Wells SA Jr: Parathyroid autotransplantation. Surgery 113: 130, 1993PubMedGoogle Scholar
  552. 552.
    Rothmund M, Wagner PK, Schark C: Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. WJ Surg 15: 745, 1991Google Scholar
  553. 553.
    White JV, LoGerfo P, Feind C, Weber C: Autologous parathyroid transplantation. Lancet 2: 461, 1983PubMedGoogle Scholar
  554. 554.
    Ellis HA: Fate of long term parathyroid autografts in patients with chronic renal failure treated by parathyroidectomy: a histopathological study of autografts, parathyroid glands and bone. Histopathol 13: 289, 1988Google Scholar
  555. 555.
    Gilmour JR: The gross anatomy of the parathyroid glands. J Pathol Bacteriol 46: 133, 1938Google Scholar
  556. 556.
    Wang C et al.: Hyperfunctioning supernumerary parathyroid glands. Surg Gynecol Obstet 148: 711, 1979PubMedGoogle Scholar
  557. 557.
    Gordon HE, Coburn JW, Passaro E: Surgical management of secondary hyperparathyroidism. Arch Surg 104: 520, 1972PubMedGoogle Scholar
  558. 558.
    Sicard GA, Wells SA Jr: Surgical treatment of secondary hyperparathyroidism. in Surgery of the Thyroid and Parathyroid Glands, edited by Kaplan EL, Edinburgh, Churchill Livingstone, 1983, p 243Google Scholar
  559. 559.
    Kinnaert P, Salmon I, Decoster-Gervy C et al.: Total parathyroidectomy and presternal subcutaneous implantation of parathyroid tissue for renal hyperparathyroidism. Surg Ginec Obst 176: 135, 1993Google Scholar
  560. 560.
    Felsenfeld AJ, Gutman RA, Llach F: Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient. Mineral Electrolyte Metab 10: 166, 1984Google Scholar
  561. 561.
    Litchman MB, Kinder BK, Johnson BM: Calcium requirements in ESRD patients after total parathyroidectomy with autotransplantation. Dial Transplant 16: 611, 1987Google Scholar
  562. 562.
    Shpitz B, Korzets Z, Dimbar A et al.: Immediate postoperative management of parathyroidectomy hemodialized patients. Dial Transplant 15: 507, 1986Google Scholar
  563. 563.
    Fine EJ: Parathyroid imaging: Its current status and future role. Semin Nucl Med 17: 350, 1987PubMedGoogle Scholar
  564. 564.
    Giangrande A, Cantu P, Solbiati L, Ravetto C: Ultrasonically guided fine-needle alcohol injection as an adjunct to medical treatment in secondary hyperparathyroidism. Proc Eur Dial Transplant Assoc 21: 895, 1984Google Scholar
  565. 565.
    Giangrande A, Castiglioni A, Solbiati L, Allaria P: Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 7: 412, 1992PubMedGoogle Scholar
  566. 566.
    Page B, Zingraff J, Souberbielle JC et al.: Correction of severe hyperparathyroidism in two dialysis patients: surgical removal versus percutaneous ethanol injection. Am J Kidney Dis 19: 378, 1992PubMedGoogle Scholar
  567. 567.
    Takeda S, Michigishi T, Takazakura E: Successful ultrasonically guided percutaneous ethanol injection for secondary hyperparathyroidism. Nephron 62: 100, 1992PubMedGoogle Scholar
  568. 568.
    Milliner DS, Hercz G, Miller JH et al.: Clearance of aluminum by hemodialysis. Effect of desferrioxamine. Kidney Int 20(Suppl 18): S100, 1986Google Scholar
  569. 569.
    Trapp G: Interactions of aluminum with cofactors, enzymes, and other proteins. Kidney Int 29(Suppl 18): S12, 1986Google Scholar
  570. 570.
    De Broe ME, Drueke TB, Ritz E: Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 8(Suppl 1): 1, 1993Google Scholar
  571. 571.
    Freemont AJ et al.: Water treatment alone allows removal of aluminum from bone and reversal of the calcification defect in aluminum-related osteodystrophy. Abstract Book, IXth International Congress Nephrology 48A, 1984Google Scholar
  572. 572.
    Ackrill P, Ralston AJ, Day J, Hodge K: Successful removal of aluminum from patients with dialysis encephalopathy. Lancet 2: 692, 1980PubMedGoogle Scholar
  573. 573.
    Vasilakakis DM, D’Haese PC, Lamberts LV et al.: Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 41: 1400, 1992PubMedGoogle Scholar
  574. 574.
    Molitoris BA, Alfrey AC, Alfrey PS: Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 34: 98, 1988PubMedGoogle Scholar
  575. 575.
    Romero R, Novoa D, Otero S et al.: Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin. Nephron 63: 164, 1993PubMedGoogle Scholar
  576. 576.
    Gallant S, Boyden M, Gallant L et al.: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 83: 1085, 1987PubMedGoogle Scholar
  577. 577.
    Oliveri NF, Buncic R, Chew E: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine. N Engl J Med 314: 868, 1986Google Scholar
  578. 578.
    Cases A, Kelly J, Sabater J et al.: Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 29: 176, 1988PubMedGoogle Scholar
  579. 579.
    Walker JA, Sherman RA, Eisinger RP: Thrombocytopenia associated with intravenous desferrioxamine. Am J Kidney Dis 6: 254, 1985PubMedGoogle Scholar
  580. 580.
    Sherrard DJ, Walker JA, Boykin J: Precipitation of dialysis dementia by deferoxamine treatment of aluminum related bone disease. Am J Kidney Dis 12: 126, 1988PubMedGoogle Scholar
  581. 581.
    Gallant T, Freedman MH, Vellend H, Francombe WH: Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med 314: 1643, 1986PubMedGoogle Scholar
  582. 582.
    Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 18: 660, 1991PubMedGoogle Scholar
  583. 583.
    Boelaert JR, van Roost G, Vergauwe PL et al.: The role of desferrioxamine in dialysis associated mucormycosisis. Clin Nephrol 29: 261, 1988PubMedGoogle Scholar
  584. 584.
    Van Cutsem J, Boelaert JR: Effects of deferoxamine, feroxamine and iron on experimental mucormyucosis (zygomycosis). Kidney Int 36: 10618, 1989Google Scholar
  585. 585.
    Boelaert JR, de Locht M, Van Cutsem J et al.: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 91: 19796, 1993Google Scholar
  586. 586.
    Cannata JB, Fernandez JL, Douthat W et al.: Aluminum (Al) transfer in dialysis: effect of different membranes, type of dialysis and forms of desferroxamine (DFO) administration. J Am Soc Nephrol 3: 671, 1992Google Scholar
  587. 587.
    Canavese C, Gurioli L, D’Amicone M et al.: Kinetics of aluminoxamine and feroxamine chelates in dialysis patients. Nephron 60: 411, 1992PubMedGoogle Scholar
  588. 588.
    Cannata JB, Elorriaga R, Menendez P et al.: A new orally active chelator in the treatment of aluminium (Al) overload. J Am Soc Nephrol 3: 671, 1992Google Scholar
  589. 589.
    Torres A, Hernandez D, Concepcion M et al.: Higher levels of intact parathyroid hormone (i-PTH) are necessary to maintain a normal bone remodelling in dialysis patients (DP). J Am Soc Nephrol 3: 677, 1992Google Scholar
  590. 590.
    Hercz G, Pei Y, Sherrard DJ, Chan W: Aplastic osteodystrophy: effect of lowering dialysate calcium. J Am Soc Nephrol 4: 697, 1993Google Scholar
  591. 591.
    Heynen G, Kanis JA, Oliver DO, Earnshaw M: Evidence that endogenous calcitonin protects against renal bone disease. Lancet 2: 1322, 1976Google Scholar
  592. 592.
    Delano BG et al.: A trial of calcitonin therapy in renal osteodystrophy. Nephron 11: 287, 1973PubMedGoogle Scholar
  593. 593.
    Fleisch H, Russell RGC, Francis MD: Diphosphonates inhibit hydroxiapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262, 1969PubMedGoogle Scholar
  594. 594.
    Sahni M, Guenther HL, Fleisch H et al.: Blsphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest, 1993Google Scholar
  595. 595.
    Malluche HH: The possible use of bisphosphonates in the treatment of renal osteodystrophy. Clin Nephrol 38(Suppl 1): S87, 1992Google Scholar
  596. 596.
    D’Amour P, Jobin J, Hamel L, L’Ecuyer N: IPTH values during hemodialysis: role of ionized Ca,dialysis membranes and iPTH assays. Kidney Int 38: 308, 1993Google Scholar
  597. 597.
    Gueris J, Fournier A, Sebert JL et al.: Comparative effects of dialysis with cuprophan versus polyacrilonltrile membranes on plasma immunoreactive parathyroid hormone levels in patients on chronic hemodialysis. Calcif Tissue Res 22: 34, 1977Google Scholar
  598. 598.
    Morachiello P, Landini S, Fracasso A et al.: Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients. Blood Purif 9: 148, 1991PubMedGoogle Scholar
  599. 599.
    Henderson RG, Russell RGG, Earnshaw M: Loss of metacarpal and iliac bone in chronic renal failure: influence of haemodialysis, parathyroid activity, type of renal disease, physical activity and heparin consumption. Clin Sci 56:317, 1979PubMedGoogle Scholar
  600. 600.
    Jaffe MD, Wellis PW: Multiple fractures associated with long term sodium heparin therapy. JAMA 193: 152, 1965Google Scholar
  601. 601.
    Griffith GC, Nichols G, Asher JD, Flanagan B: Heparin osteoporosis. JAMA 195: 1089, 1966Google Scholar
  602. 602.
    Majdalani G, Chomant J, Kachko A et al.: Kinetics of technetium-labeled heparin in hemodialyzed patients. Kidney Int 43(Suppl 41): S131, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Francisco Llach
    • 1
  1. 1.Beth Israel Medical CenterNewarkUSA

Personalised recommendations